US20080260819A1 - Sustained release compositions of drugs - Google Patents

Sustained release compositions of drugs Download PDF

Info

Publication number
US20080260819A1
US20080260819A1 US12/112,937 US11293708A US2008260819A1 US 20080260819 A1 US20080260819 A1 US 20080260819A1 US 11293708 A US11293708 A US 11293708A US 2008260819 A1 US2008260819 A1 US 2008260819A1
Authority
US
United States
Prior art keywords
drug
composition
microparticles
acid
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/112,937
Inventor
Alison B. Fleming
Roman V. Rariy
Jane Hirsh
Alexander M. Klibanov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Collegium Pharmaceutical Inc
Original Assignee
Collegium Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30119451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20080260819(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US12/112,937 priority Critical patent/US20080260819A1/en
Application filed by Collegium Pharmaceutical Inc filed Critical Collegium Pharmaceutical Inc
Assigned to COLLEGIUM PHARMACEUTICAL, INC. reassignment COLLEGIUM PHARMACEUTICAL, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HIRSH, JANE, KLIBANOV, ALEXANDER M., FLEMING, ALISON B., RARIY, ROMAN V.
Publication of US20080260819A1 publication Critical patent/US20080260819A1/en
Priority to US12/473,073 priority patent/US8557291B2/en
Priority to US12/965,572 priority patent/US8840928B2/en
Priority to US14/054,513 priority patent/US9248195B2/en
Priority to US14/320,086 priority patent/US9682075B2/en
Priority to US14/321,125 priority patent/US20150005332A1/en
Priority to US14/946,275 priority patent/US9592200B2/en
Priority to US15/457,153 priority patent/US20170182032A1/en
Priority to US15/606,112 priority patent/US10004729B2/en
Priority to US15/727,134 priority patent/US10525053B2/en
Priority to US16/017,099 priority patent/US20190167662A1/en
Priority to US16/697,938 priority patent/US20200093820A1/en
Priority to US16/932,647 priority patent/US20200345723A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5052Proteins, e.g. albumin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse

Definitions

  • the present invention is generally in the field of pharmaceutical compositions, and specifically relates to compositions that are designed to provide a sustained release of drug over time after oral administration.
  • Sustained release pharmaceutical formulations which release drug over an extended period of time, are widely used in the pharmaceutical industry. Such formulations provide several potential advantages to the patient including: (1) the convenience of reduced dosing frequency, (2) optimization of therapy by providing a smoother, more constant, plasma level of drug, and (3) a potential reduction in side effects.
  • oral sustained release dosage forms can be classified as diffusion-controlled, erosion-controlled or osmotic pressure-controlled.
  • control of drug release is usually achieved by dispersing the drug in an inert insoluble matrix or by coating a drug containing core with an insoluble polymeric film.
  • Erosion controlled formulations can be achieved by dispersing the drug in a slowly soluble carrier material or by coating the drug with a slowly soluble material.
  • Osmotic systems are monolithic in nature and consist of a core containing an osmotically active drug or a drug in combination with an osmotically active salt, surrounded by a semi-permeable membrane containing a small orifice.
  • sustained release dosage forms Although many types of sustained release dosage forms have been described, currently available sustained release dosage forms have some inherent disadvantages. Monolithic dosage forms, such as tablets or capsules, can be difficult for some patients to swallow. Since sustained release formulations can be subject to dose dumping when they are crushed, these products come with specific instructions not to break, chew or crush them. While there are some available multiparticulate formulations (such as particles-in-capsule and sachet) that can be administered as particles, for example after sprinkling in applesauce, such formulations are still potentially dangerous if the particles are accidentally chewed, broken or their physical integrity is compromised, thus resulting in the destruction of the sustained release feature.
  • multiparticulate formulations such as particles-in-capsule and sachet
  • compositions can be used to improve the convenience and safety of administration when a sustained release dosage form is desired.
  • the drug is chemically modified to increase its lipophilicity.
  • the formulation contains lipophilic or water-insoluble materials or is made using a process which increases the lipophilicity and/or water-insolubility of the composition.
  • the individual drug-containing microparticles or drug particles are coated with one or more independent coating layers.
  • compositions retard the release of drug, even if the physical integrity of the dosage form is compromised (for example, by breaking or chewing).
  • compositions when administered orally, result in a desired drug release profile.
  • a desired drug release profile provides a therapeutic effect for an extended period of time, typically from 6 to 24 hours. Additional compositions are provided which achieve a small immediate dose that precedes the sustained release of drug.
  • the compositions disclosed herein may optionally include a combination of active pharmaceutical agents.
  • sustained-release pharmaceutical compositions Disclosed herein are sustained-release pharmaceutical compositions and the method of making and using the compositions.
  • composition refers to the drug dosage unit for administration to a patient. This may also be used in reference to the final dosage form (tablet or capsule) or to components of the final dosage form (microparticles or coated microparticles).
  • sustained release formulations are subject to dose dumping when chewed or crushed because mechanical destruction of the dosage form exposes the encapsulated drug and allows for immediate dissolution of the drug into aqueous media.
  • Two properties of the dosage form that contribute to this outcome are (1) the ease with which drug is exposed when the compositions are broken or chewed and (2) the high water solubility of the drug salt form.
  • the drug is modified to increase its lipophilicity and, in additional preferred embodiments, is then homogeneously dispersed within a material that is either slowly soluble or not soluble in water and subsequently formulated into microparticles.
  • the drug may be present in the form of discrete particles or may be partially or fully dispersed in the carrier material on a molecular level.
  • the sustained release composition preferably includes a drug modified to increase its lipophilicity.
  • the drug is homogenously dispersed within microparticles composed of a material that is either slowly soluble in water or water insoluble.
  • the compositions slow the release of drug if the dosage form is broken or chewed and the resulting material is swallowed since most of the drug will remain associated with or entrapped within portions of the core material of the microparticles.
  • the drug containing microparticles or individual drug particles are coated with one or more coating layers.
  • Exemplary drug agents useful for forming the composition described herein include, but are not limited to, analeptic agents; analgesic agents; anesthetic agents; antiasthmatic agents; antiarthritic agents; anticancer agents; anticholinergic agents; anticonvulsant agents; antidepressant agents; antidiabetic agents; antidiarrheal agents; antiemetic agents; antihelminthic agents; antihistamines; antihyperlipidemic agents; antihypertensive agents; anti-infective agents; antiinflammatory agents; antimigraine agents; antineoplastic agents; antiparkinsonism drugs; antipruritic agents; antipsychotic agents; antipyretic agents; antispasmodic agents; antitubercular agents; antiulcer agents; antiviral agents; anxiolytic agents; appetite suppressants; attention deficit disorder and attention deficit hyperactivity disorder drugs; cardiovascular agents including calcium channel blockers, antianginal agents, central nervous system (“CNS”) agents, beta-blockers and antiarrhythmic agents; central nervous system stimul
  • Drugs that are most preferable include those that are currently formulated as sustained or controlled release compositions, where drug release is intended to occur over a prolonged period of time through the gastrointestinal tract, and immediate or burst release is undesirable.
  • agents currently formulated in sustained or controlled release formulations include, but are not limited to, acetaminophen, acetazolamide, albuterol, alfuzosin, alprazolam, amoxicillin, amphetamine, aspirin, brompheniramine, bupropion, carbamazepine, carbidopa, carbinoxamine, cetirizine, chlorpheniramine, ciprofoxacin, clarithromycin, clavulanate, clorazepate, colestipol, desloratidine, dexbrompheniramine, dexmethylphenidate, dextroamphetamine, dextromethorphan, diclofenac, diethylpropion, diltiazem, dipyridamole
  • drug drug
  • active agent drug
  • pharmacologically active agent are used interchangeably herein to refer to a chemical compound that induces a desired pharmacological and/or physiological effect.
  • pharmaceutically acceptable derivatives of those active agents specifically mentioned herein including, but not limited to, salts, solvates, hydrates, complexes with one or more molecules, prodrugs, active metabolites, analogs, and the like.
  • active agent pharmaceutically active agent
  • drug drug
  • active agent pharmaceutically active agent
  • drug drug
  • a particular drug such as oxycodone
  • pharmaceutically acceptable salts, solvates, hydrates, complexes with one or more molecules, prodrugs, active metabolites, and analogs it is to be understood as including the active agent per se as well as pharmaceutically acceptable salts, solvates, hydrates, complexes with one or more molecules, prodrugs, active metabolites, and analogs.
  • compositions disclosed herein contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, d-isomers, 1-isomers, the racemic mixtures thereof, compounds of different spacial conformations, and other mixtures thereof, as falling within the scope of the invention.
  • Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • the pharmaceutically acceptable salts of the compounds can be synthesized from the parent compound, which contains a basic or acidic moiety, by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.
  • the salt can also be formed as part of the manufacturing process for the composition.
  • fatty acid salts such as oleate, myristate, palmitate or stearate
  • suitable salts are found in Remington's Pharmaceutical Sciences, 20th ed., Lippincott Williams & Wilkins, Baltimore, Md., 2000, p. 704, the disclosure of which is hereby incorporated by reference.
  • composition described herein can include a combination of active pharmaceutical agents.
  • the solubility characteristics of a drug are altered prior to incorporation into the formulation. Modification of the drug to produce a more lipophilic derivative serves to reduce the water solubility of the drug and thus reduces the aqueous extractability. Furthermore, if the drug is made more lipophilic, it can be solubilized in the molten carrier material, rather than physically dispersed in a particulate form. When drug is solubilized in the carrier material it is difficult to extract drug from the resulting intimately dispersed composition.
  • lipophilic derivative and “lipophililic drug derivative”, as used herein, refer to derivatives of the drug that are less soluble in water than the most soluble salt of the drug.
  • the most soluble salt is selected from either drug alkaline metal salts (for acidic drugs) or salts of the drug with inorganic acids (for basic drugs). The examples of the latter include, but are not limited to, hydrohalates, sulfates, and nitrates.
  • drug is made more lipophilic by eliminating or reducing the overall charge of the drug molecule.
  • a water soluble salt such as hydrochloride, sulfate, or maleate
  • a water soluble salt such as sodium, potassium, or the like
  • a free acid in the case of an acidic drug, a water soluble salt (such sodium, potassium, or the like) can be converted to a free acid.
  • the drug's lipophilicity is increased by forming a salt between a drug molecule and a charged compound.
  • the lipophilicity, or water solubility, of the resulting salt can be manipulated by varying the counter-ion.
  • lipophilic acids or amines with chain lengths between C 5 -C 30 are lipophilic counter-ion candidates.
  • Some specific examples include, but are not limited to, linoleic acid, octanoic acid, lauric acid, stearic acid, palmitic acid, lauryl sulfate, oleic acid, octyl amine, lauryl amine, stearyl amine, palmityl amine, linoleyl amine, and oleyl amine.
  • Other salts which may increase lipophilicity and, hence, lipid solubility relative to the parent drug compound include, but are not limited to, pectinate, tannate, phytate, salicylate, saccharinate, acesulfamate, gallate, and terephthalate salts.
  • the counter-ion used for salt formation may also be polymeric in nature.
  • anionic copolymers based on methacrylic acid and methyl methacrylate sold under the trade name Eudragit (e.g., Eudragit L 100 and Eudragit S 100), acrylic acid polymers, and crosslinked acrylic acid polymers may be used to form a salt with drug molecules.
  • Naturally occurring polymers and their derivatives, for example, carboxymethylcellulose, may also be used to form a salt with the drug molecules.
  • the number of drug molecules reacted with the polymer to form a salt may or may not be equimolar with respect to the number of salt-forming sites on the polymer chain.
  • a salt composed of a pharmaceutically active agent and a fatty acid or amine can be accomplished by a melt process, with or without the use of a solvent.
  • One or more fatty acids or amines are heated above their melting point and the pharmaceutically active agent, in free base or acid form, is added to the molten fatty acid or amine, respectively, either directly or after dissolution of the active agent in an appropriate solvent.
  • the fatty acid or fatty amine may be present in an equimolar amount or may be present in excess with respect to the free base or free acid of the active agent.
  • a drug is covalently modified to increase its lipophilicity.
  • a lipophilic compound can be covalently attached to a drug molecule via an ester or amide linkage. Such drug derivatives are cleaved in vivo, thus releasing the parent compound.
  • microparticle refers to a composition including a drug dispersed within a carrier material
  • coated microparticle refers to a composition including a drug containing microparticle or a drug particle coated with one or more coating layers of material. Microparticles and coated microparticles have a size range of 10 to 3000 microns in diameter.
  • drug is preferably homogeneously dispersed in the form of fine particles within the carrier material. More preferably, drug is partially solubilized in molten carrier material or partially dissolved with the carrier material in a mutual solvent during the formulation of the microparticles. Most preferably, drug is completely solubilized in the molten carrier material or completely dissolved with the carrier material in a co-solvent during the formulation of the microparticles. This is accomplished through the selection of materials and the manner in which they are processed.
  • Carrier materials appropriate for the fabrication of drug containing microparticles are either slowly soluble in water or insoluble in water, but capable of degrading within the GI tract by means including enzymatic degradation, surfactant action of bile acids and mechanical erosion.
  • slowly soluble in water refers to materials that are not dissolved in water within a period of 30 minutes.
  • Preferred examples include fats, fatty substances, waxes, wax-like substances and mixtures thereof.
  • Suitable fats and fatty substances include fatty alcohols (such as lauryl, myristyl stearyl, cetyl or cetostearyl alcohol), fatty acids and derivatives, including but not limited to fatty acid esters, fatty acid glycerides (mono-, di- and tri-glycerides), and hydrogenated fats.
  • fatty alcohols such as lauryl, myristyl stearyl, cetyl or cetostearyl alcohol
  • fatty acids and derivatives including but not limited to fatty acid esters, fatty acid glycerides (mono-, di- and tri-glycerides), and hydrogenated fats.
  • Specific examples include, but are not limited to hydrogenated vegetable oil, hydrogenated cottonseed oil, hydrogenated castor oil, hydrogenated oils available under the trade name Sterotex®, stearic acid, cocoa butter, glyceryl behenate (available under the trade name COMPRITOL 888®), glyceryl dipalmitostearate (available
  • Suitable waxes and wax-like materials include natural or synthetic waxes, hydrocarbons, and normal waxes. Specific examples of waxes include beeswax, glycowax, castor wax, carnauba wax, paraffins and candelilla wax. As used herein, a wax-like material is defined as any material which is normally solid at room temperature and has a melting point of from about 30 to 300° C.
  • rate-controlling (wicking) agents may be formulated along with the fats or waxes listed above.
  • rate-controlling materials include certain starch derivatives (e.g., waxy maltodextrin and drum dried corn starch), cellulose derivatives (e.g., hydroxypropylmethylcellulose, hydroxypropylcellulose, methylcellulose, and carboxymethylcellulose), alginic acid, lactose and talc.
  • a pharmaceutically acceptable surfactant for example, lecithin may be added to facilitate the degradation of such microparticles.
  • Proteins which are water insoluble are preferred carrier materials for the formation of drug containing microparticles. Additionally, proteins, polysaccharides and combinations thereof which are water soluble can be formulated with drug into microparticles and subsequently cross-linked to form an insoluble network.
  • Certain polymers may also be used as carrier materials in the formulation of drug containing microparticles.
  • Suitable polymers include ethylcellulose and other natural or synthetic cellulose derivatives. Polymers which are slowly soluble and form a gel in an aqueous environment, such as hydroxypropyl methylcellulose or polyethylene oxide may also be suitable as carrier materials for drug containing microparticles.
  • Encapsulation or incorporation of drug into carrier materials to produce drug containing microparticles can be achieved through known pharmaceutical formulation techniques.
  • the carrier material In the case of formulation in fats, waxes or wax-like materials, the carrier material is heated above its melting temperature and the drug is added to form a mixture including drug particles suspended in the carrier material, drug dissolved in the carrier material, or a mixture thereof.
  • Microparticles can be subsequently formulated through several methods including, but not limited to, the processes of congealing, extrusion, spray chilling or aqueous dispersion.
  • wax is heated above its melting temperature, drug is added, and the molten wax-drug mixture is congealed to form solid, spherical particles via a spraying or spinning disk process.
  • the molten wax-drug mixture can be extruded and spheronized to form pellets or beads.
  • Detailed descriptions of these processes can be found in “Remington—The science and practice of pharmacy”, 20 th Edition, Jennaro et. Al., (Phila, Lippencott, Williams, and Wilkens, 2000.
  • Detailed descriptions of the spinning disk process can be found in U.S. Pat. Nos. 3,015,128 and 7,261,529.
  • a solvent evaporation technique to produce drug containing microparticles.
  • drug and carrier material are co-dissolved in a mutual solvent and microparticles can subsequently be produced by several techniques including, but not limited to, forming an emulsion in water or other appropriate media, spray drying, using a spinning disk process or by evaporating off the solvent from the bulk solution and milling the resulting material.
  • processing conditions can be used to influence the dispersion of the drug within water-insoluble or slowly water-soluble material.
  • the temperature, agitation rate and time of processing will influence the degree of dissolution achieved. More specifically, a more homogenous dispersion may be achieved with a higher temperature, faster stirring rate and longer processing time.
  • Ultrasound can also be applied to the molten mixture to increase the degree of dispersion and/or the rate of dissolution of the drug.
  • drug in a particulate form is homogeneously dispersed in a water-insoluble or slowly water soluble material.
  • the drug powder itself may be milled to generate fine particles prior to formulation. The process of jet milling, known in the pharmaceutical art, can be used for this purpose.
  • drug in a particulate form is homogeneously dispersed in a wax or wax like substance by heating the wax or wax like substance above its melting point and adding the drug particles while stirring the mixture.
  • a pharmaceutically acceptable surfactant may be added to the mixture to facilitate the dispersion of the drug particles.
  • a homogeneous molten mixture in which the drug particles are completely dissolved, can be achieved in the following manner.
  • the one or more fatty acid(s) are heated above their melting point but below the melting point of the active agent.
  • the active agent in free base form is mixed with the molten fatty acid until a clear, homogeneous mixture is formed.
  • the active agent may be added in the solid form or may first be dissolved in an appropriate solvent.
  • one or more fats, fatty substances, waxes, and/or wax-like substances are co-melted into the mixture, either before the addition of the active agent or following the addition of the active agent.
  • An analogous composition may be formed using the free acid of the active agent, one or more fatty amines, and, optionally, one or more fats, fatty substances, waxes, and/or wax-like substances.
  • drug containing microparticles or drug particles are encapsulated.
  • Drug containing microparticles can be encapsulated in water insoluble materials, slowly water soluble materials, or materials with pH dependent solubilities.
  • any coating procedure which provides a contiguous coating on each microparticle without significant agglomeration of particles may be used.
  • Coating procedures known in the pharmaceutical art including, but not limited to, fluid bed coating processes and microencapsulation may be used to obtain appropriate coatings. Detailed descriptions of these processes can be found in “Remington—The science and practice of pharmacy”, 20 th Edition, Jennaro et. Al., (Phila, Lippencott, Williams, and Wilkens, 2000.
  • the water-insoluble coating materials may be any of a large number of natural or synthetic film-formers used singly, in admixture with each other, and in admixture with plasticizers, pigments and other substances to alter the characteristics of the coating.
  • a water-insoluble but water-permeable diffusion barrier may consist of ethyl cellulose, methyl cellulose and mixtures thereof.
  • the water-permeable diffusion barrier may also include ammonio methacrylate copolymers sold under the trade name EUDRAGIT® (Rohm Pharma), such as EUDRAGIT RS, EUDRAGIT RL, EUDRAGIT NE and mixtures thereof.
  • Other synthetic polymers for example, polyvinyl acetate (available under the trade name KOLLICOAT®), can also be used to form water-insoluble but permeable coatings.
  • the coating may also include a water-insoluble but enzymatically degradable material.
  • the substrates of digestive enzymes are naturally water-insoluble and can be utilized in the formulation without further processing.
  • Solid esters of fatty acids which are hydrolyzed by lipases, can be spray coated onto microparticles or drug particles. Mixtures of waxes (beeswax, carnauba wax, etc.) with glyceryl monostearate, stearic acid, palmitic acid, glyceryl monopalmitate and cetyl alcohol will also form films that are dissolved slowly or broken down in the GI tract. Zein is an example of a naturally water-insoluble protein.
  • cross-linking agents In addition to these cross-linking agents, oxidized and native sugars have been used to cross-link gelatin (Cortesi, R., et al., Biomaterials 19 (1998) 1641-1649). Cross-linking can also be accomplished using enzymatic means; for example, transglutaminase has been approved as a GRAS substance for cross-linking seafood products. Finally, cross-linking can be initiated by physical means such as thermal treatment, UV irradiation and gamma irradiation.
  • a water soluble protein can be spray coated onto the microparticles and subsequently cross-linked by the one of the methods described above.
  • drug containing microparticles can be microencapsulated within protein by coacervation-phase separation (for example, by the addition of salts) and subsequently cross-linked.
  • suitable proteins for this purpose include gelatin, albumin, casein, and gluten.
  • Polysaccharides can also be cross-linked to form a water-insoluble network. For many polysaccharides, this can be accomplished by reaction with calcium salts or multivalent cations which cross-link the main polymer chains. Pectin, alginate, dextran, amylose and guar gum are subject to cross-linking in the presence of multivalent cations. Complexes between oppositely charged polysaccharides can also be formed; pectin and chitosan, for example, can be complexed via electrostatic interactions. Insoluble coatings can be formed on particles in this fashion. It should be noted that in many cases polysaccharides are broken down specifically by enzymes produced by bacteria within the colon.
  • a water-insoluble but enzymatically degradable coating including both a protein and a polysaccharide can be produced if the components are oppositely charged polyelectrolytes. Under the proper temperature, pH, and concentrations, the two polymers can interact through their opposite electrical charges and form a water-insoluble complex. If a core particle is present at the time the complex phase separates, it will be coated. For example, gelatin and gum arabic can be coated onto a core particle utilizing this process.
  • the complex can be made irreversibly insoluble by subsequent cross-linking induced by chemical or physical means.
  • Coating materials may also include a pH sensitive polymer which is insoluble in the acid environment of the stomach, and soluble in the more basic environment of the GI tract.
  • a coating is thus an enteric coating, creating a dosage form designed to prevent drug release in the stomach. Preventing drug release in the stomach has the advantage of reducing side effects associated with irritation of the gastric mucosa, and of minimizing exposure of drug to very low pH. Avoiding release within the stomach can be achieved using enteric coatings known in the art.
  • the enteric coated formulation remains intact or substantially intact in the stomach, however, once the formulation reaches the small intestines, the enteric coating dissolves and exposes either drug-containing carrier particles or drug-containing carrier particles coated with extended release coating.
  • the enteric coated particles can be prepared as described in “Pharmaceutical dosage form tablets”, eds. Liberman et. al. (New York, Marcel Dekker, Inc., 1989), “Remington—The science and practice of pharmacy”, 20th ed., Lippincott Williams & Wilkins, Baltimore, Md., 2000, and “Pharmaceutical dosage forms and drug delivery systems”, 6th Edition, Ansel et. al., (Media, Pa. Williams and Wilkins, 1995).
  • suitable coating materials include, but are not limited to, cellulose polymers, such as cellulose acetate phthalate, hydroxypropyl cellulose, hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate; polyvinyl acetate phthalate, acrylic acid polymers and copolymers, and certain methacrylic resins that are commercially available under the trade name EUDRAGIT® (Rohm Pharma). Additionally the coating material may contain conventional carriers such as plasticizers, pigments, colorants, glidants, stabilization agents, and surfactants.
  • the particles may be desirable to coat the particles with a coating which is soluble in aqueous solutions but insoluble in hydroalcoholic solutions.
  • the coating material may or may not have pH sensitive solubility in aqueous solutions.
  • insoluble polymers and pH dependent polymers can produce a pH dependent sustained release profile.
  • insoluble polymers e.g., ethylcellulose
  • water-soluble polymers e.g., HPMC or PEG
  • pH dependent swellable polymers e.g., carboxyvinylpolymer
  • a drug is homogeneously dispersed, in a fine particulate form, within a water-insoluble or slowly water soluble material and the mixture is formulated into microparticles.
  • a drug is partially dissolved within a water-insoluble or slowly water soluble material during the manufacturing process, for example, by mixing at a temperature above the melting point of the carrier material, and the mixture is formulated into microparticles.
  • a drug is fully dissolved within a water-insoluble or slowly water soluble material during the manufacturing process, for example, by mixing at a temperature above the melting point of the carrier material, and the mixture is formulated into microparticles.
  • the drug containing microparticles where the drug is homogeneously dispersed in a particulate form, or has been partially or fully dissolved within the carrier material during the manufacturing process, are coated with one or more coatings to form coated microparticles.
  • microparticles, coated microparticles, or a mixture thereof are formed into a solid dosage form suitable for oral administration.
  • microparticles or coated microparticles can be incorporated into hard capsules, dispersed within a soft gelatin capsule, or combined with appropriate excipients and tableted by compression.
  • Dosage forms can include one or more drugs. If the drugs are compatible, several different drugs can be incorporated into the same microparticle composition or coated microparticle composition.
  • the drugs can be incorporated into separate microparticle compositions where a first drug is formulated into microparticle compositions or coated microparticle compositions described herein and one or more additional drugs are incorporated into microparticle compostions or coated microparticle compositions described herein, sustained release compositions known in the art or immediate release compositions known in the art.
  • the compositions including the different drugs are formulated into a single solid dosage form suitable for oral administration, for example, they can be incorporated into a gelatin capsule, or combined with appropriate excipients and compressed into a tablet form.
  • immediate release dose can be incorporated into the formulation in several ways. Immediate release microparticles can be made utilizing standard methodologies and formulated along with sustained release microparticle and/or coated microparticle compositions in a suitable oral dosage form. Alternatively, a coating containing drug which is available for immediate release can be placed on a tablet including sustained release microparticle and/or coated microparticle compositions plus appropriate excipients.
  • an immediate dose of drug can be granulated or blended with rapidly dissolving excipients and subsequently compressed (1) as one layer of bi-layer tablets in which the sustained release microparticle and/or coated microparticle compositions are compressed as the other layer, or (2) as the outer layer of compression-coated tablets in which the sustained release microparticle and/or coated microparticle compositions are compressed as the inner core, or (3) into tablets in which sustained release microparticle and/or coated microparticle compositions are embedded.
  • Optional excipients present in the oral dosage form including abuse deterrent microparticles or coated microparticles include, but are not limited to diluents, binders, lubricants, disintigrants, colorants, plasticizers and the like.
  • Diluents also termed “fillers,” are typically necessary to increase the bulk of a solid dosage form so that a practical size is provided for compression of tablets.
  • diluents include cellulose, dry starch, microcrystalline cellulose, dicalcium phosphate, calcium sulfate, sodium chloride confectioner's sugar, compressible sugar, dextrates, dextrin, dextrose, sucrose, mannitol, powdered cellulose, sorbitol, and lactose.
  • Binders are used to impart cohesive qualities powdered materials and can include materials such as starch, gelatin, sugars, natural and synthetic gums, polyethylene glycol, ethylcellulose, methylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, waxes and polyvinyl pyrrolidone.
  • Lubricants are used to facilitate tablet manufacture; examples of lubricants include talc, magnesium stearate, calcium stearate, hydrogenated vegetable oils stearic acid, sodium stearyl fumarate, sodium benzoate, sodium acetate, leucine, sodium oleate, sodium lauryl sulfate, magnesium lauryl sulfate and polyethylene glycol.
  • Disintegrants can be added to pharmaceutical formulations in order to facilitate “breakup” or disintegration after administration. Materials used for this purpose include starches, clays, celluloses, aligns, gums, and cross-linked polymers. A plasticizer may be included in coating materials to alter their mechanical properties.
  • plasticizers examples include benzyl benzoate, chlorobutanol, dibutyl sebacate, diethyl phthalate, glycerin, mineral oil, polyethylene glycol, sorbitol, triacetin, triethyl citrate, glycerol, etc.
  • coloring and flavoring agents may also be incorporated into the composition.
  • Food then enters the small intestine in the form of macromolecular aggregates, where it is digested into molecules near or in a form capable of being absorbed. This digestion is accomplished through the action of various enzymes which are produced in the pancreas and flow into the upper portion of the large intestine, the duodenum.
  • the enzymes synthesized in the pancreas include proteases, amylases and lipases; these enzymes are capable of breaking down proteins, starches and fats, respectively.
  • bile salts which contain both hydrophobic and hydrophilic portions, are capable of emulsifying lipids into minute droplets in order to increase the surface area available for digestion by lipases.
  • the material which remains following passage through the small intestine enters the large intestine.
  • Bacteria capable of breaking down carbohydrates not digested in the small intestine (such as cellulose) are present in large numbers this region of the digestive tract.
  • the large intestine functions to absorb water and electrolytes and to form and store feces until they are excreted.
  • an immediate release of drug is achieved within the stomach in order to provide rapid therapeutic onset.
  • the pharmaceutical drug composition is administered orally.
  • the appropriate dosage formulations can be obtained by calculation of the pharmacokinetics of the formulation, then adjusting using routine techniques to yield the appropriate drug levels based on the approved dosage forms.
  • Any suitable amount of drug containing microparticles or coated microparticles can be included in the final formulation. The selection of a suitable amount of drug containing microparticles depends on the dosage desired and is readily determined by those skilled in the art.
  • some embodiments may also be administered by other routes, including, but not limited to, rectal and nasal administration. Some embodiments may also be suitable for formulation as oral liquids.
  • the free base of oxycodone can be prepared from its hydrochloride salt by the following method: Oxycodone hydrochloride is dissolved in water and sodium carbonate was added in the amount required to neutralize hydrochloric acid. Methylene chloride is added in order to extract the formed oxycodone free base. The obtained organic layer is dried over sodium sulfate and methylene chloride is evaporated using rotary evaporator. The obtained oxycodone free base is purified by crystallization.
  • Fatty acid (myristic or stearic acid) was melted in an erlenmeyer flask in a silicone oil bath at 100° C. Note the composition was subjected to stirring and was kept under an argon blanket for this and all subsequent steps. 2.
  • Oxycodone base was introduced into the molten fatty acid and the melt was stirred until all oxycodone base dissolved and a clear liquid was formed. 3.
  • Yellow beeswax was added and melted under constant stirring.
  • Carnauba wax was added and melted under constant stirring. 5.
  • the resulting homogeneous molten solution was poured onto aluminum foil and allowed to solidify at room temperature. 6.
  • the bulk wax obtained was combined with dry ice and subjected to size reduction in a mortar and pestle. 7.
  • the dry ice was allowed to dissipate and the particles were sieved to obtain various size ranges. Particles 20-40 mesh in size (400-841 micron) were subjected to testing.
  • Example 2 In vitro testing was conducted in order to assess the influence of crushing of the microparticles produced in Example 2 on the release in simulated stomach conditions.
  • Microparticles (Formulations A, B, C or D, all 20-40 mesh in starting particle size) or tablets were crushed using a glass mortar & pestle. The resulting crushed material was placed in a dissolution vessel equipped with paddles (USP Apparatus II). 900 mL of 0.1N HCl pre-warmed to 37° C. was added to the vessels and stirring was conducted for 15 minutes. After 15 minutes the amount of oxycodone released was determined. See Table 2.
  • Example 2 release only a fraction of the total drug load in simulated stomach conditions when crushed.
  • OxyContin® a currently marketed sustained release composition, OxyContin®, releases approximately 96% of the drug load when crushed and exposed to identical conditions.
  • the drug-containing particles from Example 2 are spray coated with cellulose acetate phalate.
  • the drug containing microparticles from Example 2 and/or the coated microparticles from Example 3 are blended with a lubricant and incorporated into standard gelatin capsules.

Abstract

A sustained release pharmaceutical composition has been developed. The composition resists dose dumping when broken, crushed or chewed, which enhances the safety of the dosage form should it be accidentally or intentionally physically compromised. In the preferred embodiment, a drug is modified to increase its lipophilicity. In preferred embodiments the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles coated with one or more coating layers. The sustained release composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chewing or crushing) and the resulting material is placed in 0.1N HCl. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of diffusion, surfactant action of bile acids, mechanical erosion, and in some embodiments, enzymatic degradation.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a Continuation-in-Part of U.S. Ser. No. 10/614,866 filed on Jul. 7, 2003 entitled “Abuse-Deterrent Pharmaceutical Compositions of Opiods and Other Drugs”, which claims priority to U.S. Ser. No. 60/393,876 filed Jul. 5, 2002 entitled “Abuse-Resistant Formulations of Oxycontin and Other Drugs” by Alexander M. Klibanov, Stephen L. Buchwald, Timothy M. Swager, and Whe-Yong Lo; U.S. Ser. No. 60/436,523 filed Dec. 23, 2002 by Alison B. Fleming, Roman V. Rariy, Alexander M. Klibanov, Whe-Yong Lo, and Jane Hirsh; U.S. Ser. No. 60/443,226 filed Jan. 28, 2003 by Jane Hirsh, Alison B. Fleming, Alexander M. Klibanov, and Whe-Yong Lo; U.S. Ser. No. 60/463,514 filed Apr. 15, 2003 by Jane C. Hirsh, Alison B. Fleming, Roman V. Rariy, Stephen L. Buchwald, and Timothy M. Swager; and U.S. Ser. No. 60/463,518 filed Apr. 15, 2003 by Jane C. Hirsh, Alison B. Fleming and Roman V. Rariy. The disclosures in the applications listed above are herein incorporated by reference.
  • BACKGROUND OF THE INVENTION
  • The present invention is generally in the field of pharmaceutical compositions, and specifically relates to compositions that are designed to provide a sustained release of drug over time after oral administration.
  • Sustained release pharmaceutical formulations, which release drug over an extended period of time, are widely used in the pharmaceutical industry. Such formulations provide several potential advantages to the patient including: (1) the convenience of reduced dosing frequency, (2) optimization of therapy by providing a smoother, more constant, plasma level of drug, and (3) a potential reduction in side effects.
  • Several formulations that achieve sustained release of drug when administered orally have been described in the literature. In general, oral sustained release dosage forms can be classified as diffusion-controlled, erosion-controlled or osmotic pressure-controlled. For diffusion based systems, control of drug release is usually achieved by dispersing the drug in an inert insoluble matrix or by coating a drug containing core with an insoluble polymeric film. Erosion controlled formulations can be achieved by dispersing the drug in a slowly soluble carrier material or by coating the drug with a slowly soluble material. Osmotic systems are monolithic in nature and consist of a core containing an osmotically active drug or a drug in combination with an osmotically active salt, surrounded by a semi-permeable membrane containing a small orifice.
  • Although many types of sustained release dosage forms have been described, currently available sustained release dosage forms have some inherent disadvantages. Monolithic dosage forms, such as tablets or capsules, can be difficult for some patients to swallow. Since sustained release formulations can be subject to dose dumping when they are crushed, these products come with specific instructions not to break, chew or crush them. While there are some available multiparticulate formulations (such as particles-in-capsule and sachet) that can be administered as particles, for example after sprinkling in applesauce, such formulations are still potentially dangerous if the particles are accidentally chewed, broken or their physical integrity is compromised, thus resulting in the destruction of the sustained release feature.
  • It is therefore an object of the present invention to provide a sustained-release, multiparticulate pharmaceutical composition that resists dose dumping when accidentally broken, crushed or chewed.
  • SUMMARY OF THE INVENTION
  • Sustained release pharmaceutical compositions and the methods of making and using the composition have been developed. The compositions can be used to improve the convenience and safety of administration when a sustained release dosage form is desired. In the preferred embodiment, the drug is chemically modified to increase its lipophilicity. In other embodiments, the formulation contains lipophilic or water-insoluble materials or is made using a process which increases the lipophilicity and/or water-insolubility of the composition. In some embodiments, the individual drug-containing microparticles or drug particles are coated with one or more independent coating layers.
  • The compositions retard the release of drug, even if the physical integrity of the dosage form is compromised (for example, by breaking or chewing).
  • The pharmaceutical compositions, when administered orally, result in a desired drug release profile. Such a release profile provides a therapeutic effect for an extended period of time, typically from 6 to 24 hours. Additional compositions are provided which achieve a small immediate dose that precedes the sustained release of drug. The compositions disclosed herein may optionally include a combination of active pharmaceutical agents.
  • DETAILED DESCRIPTION OF THE INVENTION
  • Disclosed herein are sustained-release pharmaceutical compositions and the method of making and using the compositions.
  • I. Compositions
  • As used herein, “composition” or “compositions” refers to the drug dosage unit for administration to a patient. This may also be used in reference to the final dosage form (tablet or capsule) or to components of the final dosage form (microparticles or coated microparticles).
  • Currently available sustained release formulations are subject to dose dumping when chewed or crushed because mechanical destruction of the dosage form exposes the encapsulated drug and allows for immediate dissolution of the drug into aqueous media. Two properties of the dosage form that contribute to this outcome are (1) the ease with which drug is exposed when the compositions are broken or chewed and (2) the high water solubility of the drug salt form.
  • In the composition disclosed herein, one or both of these properties are altered in order to achieve a composition which resists dose dumping when chewed or broken. Specifically, in the preferred embodiment, the drug is modified to increase its lipophilicity and, in additional preferred embodiments, is then homogeneously dispersed within a material that is either slowly soluble or not soluble in water and subsequently formulated into microparticles. The drug may be present in the form of discrete particles or may be partially or fully dispersed in the carrier material on a molecular level.
  • The sustained release composition preferably includes a drug modified to increase its lipophilicity. In other preferred embodiments, the drug is homogenously dispersed within microparticles composed of a material that is either slowly soluble in water or water insoluble. The compositions slow the release of drug if the dosage form is broken or chewed and the resulting material is swallowed since most of the drug will remain associated with or entrapped within portions of the core material of the microparticles. In some embodiments the drug containing microparticles or individual drug particles are coated with one or more coating layers.
  • A. Drugs to be Formulated
  • There are many drugs that it is desirable to deliver using the compositions described herein.
  • Exemplary drug agents useful for forming the composition described herein include, but are not limited to, analeptic agents; analgesic agents; anesthetic agents; antiasthmatic agents; antiarthritic agents; anticancer agents; anticholinergic agents; anticonvulsant agents; antidepressant agents; antidiabetic agents; antidiarrheal agents; antiemetic agents; antihelminthic agents; antihistamines; antihyperlipidemic agents; antihypertensive agents; anti-infective agents; antiinflammatory agents; antimigraine agents; antineoplastic agents; antiparkinsonism drugs; antipruritic agents; antipsychotic agents; antipyretic agents; antispasmodic agents; antitubercular agents; antiulcer agents; antiviral agents; anxiolytic agents; appetite suppressants; attention deficit disorder and attention deficit hyperactivity disorder drugs; cardiovascular agents including calcium channel blockers, antianginal agents, central nervous system (“CNS”) agents, beta-blockers and antiarrhythmic agents; central nervous system stimulants; diuretics; genetic materials; hormonolytics; hypnotics; hypoglycemic agents; immunosuppressive agents; muscle relaxants; narcotic antagonists; nicotine; nutritional agents; parasympatholytics; peptide drugs; psychostimulants; sedatives; steroids; smoking cessation agents; sympathomimetics; tranquilizers; vasodilators; beta-agonist; and tocolytic agents.
  • Drugs that are most preferable include those that are currently formulated as sustained or controlled release compositions, where drug release is intended to occur over a prolonged period of time through the gastrointestinal tract, and immediate or burst release is undesirable. Specific examples of agents currently formulated in sustained or controlled release formulations include, but are not limited to, acetaminophen, acetazolamide, albuterol, alfuzosin, alprazolam, amoxicillin, amphetamine, aspirin, brompheniramine, bupropion, carbamazepine, carbidopa, carbinoxamine, cetirizine, chlorpheniramine, ciprofoxacin, clarithromycin, clavulanate, clorazepate, colestipol, desloratidine, dexbrompheniramine, dexmethylphenidate, dextroamphetamine, dextromethorphan, diclofenac, diethylpropion, diltiazem, dipyridamole, disopyramide, divalproex sodium, doxazosin, doxycycline, enalapril, etodolac, felodipine, fexofenadine, fluoxetine, fluvastatin, glipizide, guaifenesin, hyoscyamine, indomethacin, isosorbide dinitrate, isosorbide mononitrate, isradipine, ketoprofen, levodopa, loratidine, lovastatin, mesalamine, metformin, methscopolamine, methylphenidate, metoprolol, metronidazole, minocycline, morphine, naproxen, niacin, nicardipene, nifedipine, nsoldipine, nitroglycerin, orphenadrine, oxybutynin, oxycodone, oxymorphone, papaverine, paroxetine, pentoxifyline, phendimetrazine, phenylephrine, phenyloin, procainamide, propranolol, pseudophedrine, pyridostigime, quinidine, ranolazine, tamsulosin, theophylline, tolterodine, tramadol, trandolapril, venlafaxine, verapamil, and zolpidem.
  • The terms “drug”, “active agent”, and “pharmacologically active agent” are used interchangeably herein to refer to a chemical compound that induces a desired pharmacological and/or physiological effect. The terms also encompass pharmaceutically acceptable derivatives of those active agents specifically mentioned herein, including, but not limited to, salts, solvates, hydrates, complexes with one or more molecules, prodrugs, active metabolites, analogs, and the like. When the terms “active agent”, “pharmacologically active agent” and “drug” are used, or when a particular drug, such as oxycodone, is identified, it is to be understood as including the active agent per se as well as pharmaceutically acceptable salts, solvates, hydrates, complexes with one or more molecules, prodrugs, active metabolites, and analogs.
  • Certain compounds described herein may exist in particular geometric or stereoisomeric forms. The composition disclosed herein contemplates all such compounds, including cis- and trans-isomers, R- and S-enantiomers, diastereomers, d-isomers, 1-isomers, the racemic mixtures thereof, compounds of different spacial conformations, and other mixtures thereof, as falling within the scope of the invention. Additional asymmetric carbon atoms may be present in a substituent such as an alkyl group. All such isomers, as well as mixtures thereof, are intended to be included in this invention.
  • As used herein, “pharmaceutically acceptable salts” refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • The pharmaceutically acceptable salts of the compounds can be synthesized from the parent compound, which contains a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Optionally, the salt can also be formed as part of the manufacturing process for the composition. For fatty acid salts such as oleate, myristate, palmitate or stearate, this can be accomplished by melting the fatty acid, optionally along with other waxes, and adding the free base of the drug directly into this melt. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 20th ed., Lippincott Williams & Wilkins, Baltimore, Md., 2000, p. 704, the disclosure of which is hereby incorporated by reference.
  • Optionally, the composition described herein can include a combination of active pharmaceutical agents.
  • B. Drug Solubility Modification
  • In preferred embodiments, the solubility characteristics of a drug are altered prior to incorporation into the formulation. Modification of the drug to produce a more lipophilic derivative serves to reduce the water solubility of the drug and thus reduces the aqueous extractability. Furthermore, if the drug is made more lipophilic, it can be solubilized in the molten carrier material, rather than physically dispersed in a particulate form. When drug is solubilized in the carrier material it is difficult to extract drug from the resulting intimately dispersed composition.
  • The terms “lipophilic derivative” and “lipophililic drug derivative”, as used herein, refer to derivatives of the drug that are less soluble in water than the most soluble salt of the drug. The most soluble salt is selected from either drug alkaline metal salts (for acidic drugs) or salts of the drug with inorganic acids (for basic drugs). The examples of the latter include, but are not limited to, hydrohalates, sulfates, and nitrates.
  • Some of the methods that can be used to alter the drug's lipophilicity are outlined below. It is understood that two or more approaches can be combined to achieve a desired solubility profile.
  • Methods for Increasing Lipophilicity
  • In one embodiment drug is made more lipophilic by eliminating or reducing the overall charge of the drug molecule. For example, for a basic drug, a water soluble salt (such as hydrochloride, sulfate, or maleate) can be converted to a free base using techniques known in the art. Correspondingly, in the case of an acidic drug, a water soluble salt (such sodium, potassium, or the like) can be converted to a free acid.
  • In another embodiment, the drug's lipophilicity is increased by forming a salt between a drug molecule and a charged compound. In this case the lipophilicity, or water solubility, of the resulting salt can be manipulated by varying the counter-ion. In general, lipophilic acids or amines with chain lengths between C5-C30 are lipophilic counter-ion candidates. Some specific examples include, but are not limited to, linoleic acid, octanoic acid, lauric acid, stearic acid, palmitic acid, lauryl sulfate, oleic acid, octyl amine, lauryl amine, stearyl amine, palmityl amine, linoleyl amine, and oleyl amine. Other salts which may increase lipophilicity and, hence, lipid solubility relative to the parent drug compound include, but are not limited to, pectinate, tannate, phytate, salicylate, saccharinate, acesulfamate, gallate, and terephthalate salts. The counter-ion used for salt formation may also be polymeric in nature. For example, anionic copolymers based on methacrylic acid and methyl methacrylate sold under the trade name Eudragit (e.g., Eudragit L 100 and Eudragit S 100), acrylic acid polymers, and crosslinked acrylic acid polymers may be used to form a salt with drug molecules. Naturally occurring polymers and their derivatives, for example, carboxymethylcellulose, may also be used to form a salt with the drug molecules. In the case of polymeric counter-ions, the number of drug molecules reacted with the polymer to form a salt may or may not be equimolar with respect to the number of salt-forming sites on the polymer chain.
  • The formation of a salt composed of a pharmaceutically active agent and a fatty acid or amine can be accomplished by a melt process, with or without the use of a solvent. One or more fatty acids or amines are heated above their melting point and the pharmaceutically active agent, in free base or acid form, is added to the molten fatty acid or amine, respectively, either directly or after dissolution of the active agent in an appropriate solvent. The fatty acid or fatty amine may be present in an equimolar amount or may be present in excess with respect to the free base or free acid of the active agent.
  • In another embodiment, a drug is covalently modified to increase its lipophilicity. For example, a lipophilic compound can be covalently attached to a drug molecule via an ester or amide linkage. Such drug derivatives are cleaved in vivo, thus releasing the parent compound.
  • C. Drug Containing Microparticles
  • In preferred embodiments, drugs are formulated with a carrier material to form microparticles. As used herein, the term “microparticle” refers to a composition including a drug dispersed within a carrier material and “coated microparticle” refers to a composition including a drug containing microparticle or a drug particle coated with one or more coating layers of material. Microparticles and coated microparticles have a size range of 10 to 3000 microns in diameter.
  • Within microparticles, drug is preferably homogeneously dispersed in the form of fine particles within the carrier material. More preferably, drug is partially solubilized in molten carrier material or partially dissolved with the carrier material in a mutual solvent during the formulation of the microparticles. Most preferably, drug is completely solubilized in the molten carrier material or completely dissolved with the carrier material in a co-solvent during the formulation of the microparticles. This is accomplished through the selection of materials and the manner in which they are processed.
  • Carrier materials appropriate for the fabrication of drug containing microparticles are either slowly soluble in water or insoluble in water, but capable of degrading within the GI tract by means including enzymatic degradation, surfactant action of bile acids and mechanical erosion. As used herein, the term “slowly soluble in water” refers to materials that are not dissolved in water within a period of 30 minutes. Preferred examples include fats, fatty substances, waxes, wax-like substances and mixtures thereof. Suitable fats and fatty substances include fatty alcohols (such as lauryl, myristyl stearyl, cetyl or cetostearyl alcohol), fatty acids and derivatives, including but not limited to fatty acid esters, fatty acid glycerides (mono-, di- and tri-glycerides), and hydrogenated fats. Specific examples include, but are not limited to hydrogenated vegetable oil, hydrogenated cottonseed oil, hydrogenated castor oil, hydrogenated oils available under the trade name Sterotex®, stearic acid, cocoa butter, glyceryl behenate (available under the trade name COMPRITOL 888®), glyceryl dipalmitostearate (available under the trade name PRECIROL®), and stearyl alcohol. Mixtures of mono-, di- and tri-glycerides and mono- and di-fatty acid esters of polyethylene glycol, available under the trade name GELUCIRE®) are also suitable fatty materials. Suitable waxes and wax-like materials include natural or synthetic waxes, hydrocarbons, and normal waxes. Specific examples of waxes include beeswax, glycowax, castor wax, carnauba wax, paraffins and candelilla wax. As used herein, a wax-like material is defined as any material which is normally solid at room temperature and has a melting point of from about 30 to 300° C.
  • In some cases, it may be desirable to alter the rate of water penetration into the hydrophobic drug containing microparticles. To this end, rate-controlling (wicking) agents may be formulated along with the fats or waxes listed above. Examples of rate-controlling materials include certain starch derivatives (e.g., waxy maltodextrin and drum dried corn starch), cellulose derivatives (e.g., hydroxypropylmethylcellulose, hydroxypropylcellulose, methylcellulose, and carboxymethylcellulose), alginic acid, lactose and talc. Additionally, a pharmaceutically acceptable surfactant (for example, lecithin) may be added to facilitate the degradation of such microparticles.
  • Proteins which are water insoluble, such as zein, are preferred carrier materials for the formation of drug containing microparticles. Additionally, proteins, polysaccharides and combinations thereof which are water soluble can be formulated with drug into microparticles and subsequently cross-linked to form an insoluble network.
  • Certain polymers may also be used as carrier materials in the formulation of drug containing microparticles. Suitable polymers include ethylcellulose and other natural or synthetic cellulose derivatives. Polymers which are slowly soluble and form a gel in an aqueous environment, such as hydroxypropyl methylcellulose or polyethylene oxide may also be suitable as carrier materials for drug containing microparticles.
  • Encapsulation or incorporation of drug into carrier materials to produce drug containing microparticles can be achieved through known pharmaceutical formulation techniques. To create a composition that protects drug from exposure upon mechanical disruption (e.g., breaking or chewing), the drug is intimately dispersed within the carrier material. In the case of formulation in fats, waxes or wax-like materials, the carrier material is heated above its melting temperature and the drug is added to form a mixture including drug particles suspended in the carrier material, drug dissolved in the carrier material, or a mixture thereof. Microparticles can be subsequently formulated through several methods including, but not limited to, the processes of congealing, extrusion, spray chilling or aqueous dispersion. In a preferred process, wax is heated above its melting temperature, drug is added, and the molten wax-drug mixture is congealed to form solid, spherical particles via a spraying or spinning disk process. Alternatively, the molten wax-drug mixture can be extruded and spheronized to form pellets or beads. Detailed descriptions of these processes can be found in “Remington—The science and practice of pharmacy”, 20th Edition, Jennaro et. Al., (Phila, Lippencott, Williams, and Wilkens, 2000. Detailed descriptions of the spinning disk process can be found in U.S. Pat. Nos. 3,015,128 and 7,261,529.
  • For some carrier materials it may be desirable to use a solvent evaporation technique to produce drug containing microparticles. In this case drug and carrier material are co-dissolved in a mutual solvent and microparticles can subsequently be produced by several techniques including, but not limited to, forming an emulsion in water or other appropriate media, spray drying, using a spinning disk process or by evaporating off the solvent from the bulk solution and milling the resulting material.
  • In addition to modification of the drug itself, processing conditions can be used to influence the dispersion of the drug within water-insoluble or slowly water-soluble material. For example, in the case where the water in-soluble or slowly soluble material is melted and drug is fully or partially dissolved under stirring conditions, the temperature, agitation rate and time of processing will influence the degree of dissolution achieved. More specifically, a more homogenous dispersion may be achieved with a higher temperature, faster stirring rate and longer processing time. Ultrasound can also be applied to the molten mixture to increase the degree of dispersion and/or the rate of dissolution of the drug.
  • In some embodiments, drug in a particulate form is homogeneously dispersed in a water-insoluble or slowly water soluble material. To minimize the size of the drug particles within the composition, the drug powder itself may be milled to generate fine particles prior to formulation. The process of jet milling, known in the pharmaceutical art, can be used for this purpose. In some embodiments drug in a particulate form is homogeneously dispersed in a wax or wax like substance by heating the wax or wax like substance above its melting point and adding the drug particles while stirring the mixture. In this case a pharmaceutically acceptable surfactant may be added to the mixture to facilitate the dispersion of the drug particles.
  • For formulations including a pharmaceutically active agent in the free base form and one or more fatty acids, a homogeneous molten mixture, in which the drug particles are completely dissolved, can be achieved in the following manner. The one or more fatty acid(s) are heated above their melting point but below the melting point of the active agent. The active agent in free base form is mixed with the molten fatty acid until a clear, homogeneous mixture is formed. The active agent may be added in the solid form or may first be dissolved in an appropriate solvent. Optionally, one or more fats, fatty substances, waxes, and/or wax-like substances are co-melted into the mixture, either before the addition of the active agent or following the addition of the active agent. It is believed that a clear solution is formed due to the formation of a salt between the free base of the active agent and the one or more fatty acids present in the formulation. An analogous composition may be formed using the free acid of the active agent, one or more fatty amines, and, optionally, one or more fats, fatty substances, waxes, and/or wax-like substances.
  • D. Coated Drug Containing Microparticles
  • In some embodiments, drug containing microparticles or drug particles are encapsulated. Drug containing microparticles can be encapsulated in water insoluble materials, slowly water soluble materials, or materials with pH dependent solubilities.
  • In general, any coating procedure which provides a contiguous coating on each microparticle without significant agglomeration of particles may be used. Coating procedures known in the pharmaceutical art including, but not limited to, fluid bed coating processes and microencapsulation may be used to obtain appropriate coatings. Detailed descriptions of these processes can be found in “Remington—The science and practice of pharmacy”, 20th Edition, Jennaro et. Al., (Phila, Lippencott, Williams, and Wilkens, 2000.
  • The water-insoluble coating materials may be any of a large number of natural or synthetic film-formers used singly, in admixture with each other, and in admixture with plasticizers, pigments and other substances to alter the characteristics of the coating. A water-insoluble but water-permeable diffusion barrier may consist of ethyl cellulose, methyl cellulose and mixtures thereof. The water-permeable diffusion barrier may also include ammonio methacrylate copolymers sold under the trade name EUDRAGIT® (Rohm Pharma), such as EUDRAGIT RS, EUDRAGIT RL, EUDRAGIT NE and mixtures thereof. Other synthetic polymers, for example, polyvinyl acetate (available under the trade name KOLLICOAT®), can also be used to form water-insoluble but permeable coatings.
  • The coating may also include a water-insoluble but enzymatically degradable material. In some instances the substrates of digestive enzymes are naturally water-insoluble and can be utilized in the formulation without further processing. Solid esters of fatty acids, which are hydrolyzed by lipases, can be spray coated onto microparticles or drug particles. Mixtures of waxes (beeswax, carnauba wax, etc.) with glyceryl monostearate, stearic acid, palmitic acid, glyceryl monopalmitate and cetyl alcohol will also form films that are dissolved slowly or broken down in the GI tract. Zein is an example of a naturally water-insoluble protein. It can be coated onto drug containing microparticles or drug particles by spray coating or by wet granulation techniques. In addition to naturally water-insoluble materials, some substrates of digestive enzymes can be treated with cross-linking procedures, resulting in the formation of non-soluble networks. Many methods of cross-linking proteins, initiated by both chemical and physical means, have been reported. One of the most common methods to obtain cross-linking is the use of chemical cross-linking agents. Examples of chemical cross-linking agents include aldehydes (gluteraldehyde and formaldehyde), epoxy compounds, carbodiimides, and genipin. In addition to these cross-linking agents, oxidized and native sugars have been used to cross-link gelatin (Cortesi, R., et al., Biomaterials 19 (1998) 1641-1649). Cross-linking can also be accomplished using enzymatic means; for example, transglutaminase has been approved as a GRAS substance for cross-linking seafood products. Finally, cross-linking can be initiated by physical means such as thermal treatment, UV irradiation and gamma irradiation.
  • To produce a coating layer of cross-linked protein surrounding drug containing microparticles or drug particles, a water soluble protein can be spray coated onto the microparticles and subsequently cross-linked by the one of the methods described above. Alternatively, drug containing microparticles can be microencapsulated within protein by coacervation-phase separation (for example, by the addition of salts) and subsequently cross-linked. Some suitable proteins for this purpose include gelatin, albumin, casein, and gluten.
  • Polysaccharides can also be cross-linked to form a water-insoluble network. For many polysaccharides, this can be accomplished by reaction with calcium salts or multivalent cations which cross-link the main polymer chains. Pectin, alginate, dextran, amylose and guar gum are subject to cross-linking in the presence of multivalent cations. Complexes between oppositely charged polysaccharides can also be formed; pectin and chitosan, for example, can be complexed via electrostatic interactions. Insoluble coatings can be formed on particles in this fashion. It should be noted that in many cases polysaccharides are broken down specifically by enzymes produced by bacteria within the colon.
  • In some cases a water-insoluble but enzymatically degradable coating including both a protein and a polysaccharide can be produced if the components are oppositely charged polyelectrolytes. Under the proper temperature, pH, and concentrations, the two polymers can interact through their opposite electrical charges and form a water-insoluble complex. If a core particle is present at the time the complex phase separates, it will be coated. For example, gelatin and gum arabic can be coated onto a core particle utilizing this process. Optionally, the complex can be made irreversibly insoluble by subsequent cross-linking induced by chemical or physical means.
  • Coating materials may also include a pH sensitive polymer which is insoluble in the acid environment of the stomach, and soluble in the more basic environment of the GI tract. Such a coating is thus an enteric coating, creating a dosage form designed to prevent drug release in the stomach. Preventing drug release in the stomach has the advantage of reducing side effects associated with irritation of the gastric mucosa, and of minimizing exposure of drug to very low pH. Avoiding release within the stomach can be achieved using enteric coatings known in the art. The enteric coated formulation remains intact or substantially intact in the stomach, however, once the formulation reaches the small intestines, the enteric coating dissolves and exposes either drug-containing carrier particles or drug-containing carrier particles coated with extended release coating.
  • The enteric coated particles can be prepared as described in “Pharmaceutical dosage form tablets”, eds. Liberman et. al. (New York, Marcel Dekker, Inc., 1989), “Remington—The science and practice of pharmacy”, 20th ed., Lippincott Williams & Wilkins, Baltimore, Md., 2000, and “Pharmaceutical dosage forms and drug delivery systems”, 6th Edition, Ansel et. al., (Media, Pa. Williams and Wilkins, 1995). Examples of suitable coating materials include, but are not limited to, cellulose polymers, such as cellulose acetate phthalate, hydroxypropyl cellulose, hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate; polyvinyl acetate phthalate, acrylic acid polymers and copolymers, and certain methacrylic resins that are commercially available under the trade name EUDRAGIT® (Rohm Pharma). Additionally the coating material may contain conventional carriers such as plasticizers, pigments, colorants, glidants, stabilization agents, and surfactants.
  • In some cases it may be desirable to coat the particles with a coating which is soluble in aqueous solutions but insoluble in hydroalcoholic solutions. In this case the coating material may or may not have pH sensitive solubility in aqueous solutions.
  • In some cases it may be desirable to combine coating materials to produce a tailored release of drug. For example, combinations of insoluble polymers and pH dependent polymers can produce a pH dependent sustained release profile. Combinations of insoluble polymers (e.g., ethylcellulose), water-soluble polymers (e.g., HPMC or PEG) and pH dependent swellable polymers (e.g., carboxyvinylpolymer) have also been reported to produce pH dependent sustained release profiles (See, for example, Journal of Controlled Release, 2006, 111:309-315)
  • E. Dosage Forms
  • There are a number of drug compositions that meet the criteria outlined above. In one embodiment a drug is homogeneously dispersed, in a fine particulate form, within a water-insoluble or slowly water soluble material and the mixture is formulated into microparticles. In another embodiment a drug is partially dissolved within a water-insoluble or slowly water soluble material during the manufacturing process, for example, by mixing at a temperature above the melting point of the carrier material, and the mixture is formulated into microparticles. In yet another embodiment a drug is fully dissolved within a water-insoluble or slowly water soluble material during the manufacturing process, for example, by mixing at a temperature above the melting point of the carrier material, and the mixture is formulated into microparticles. In still a further embodiment, the drug containing microparticles, where the drug is homogeneously dispersed in a particulate form, or has been partially or fully dissolved within the carrier material during the manufacturing process, are coated with one or more coatings to form coated microparticles.
  • The microparticles, coated microparticles, or a mixture thereof are formed into a solid dosage form suitable for oral administration. For example, microparticles or coated microparticles can be incorporated into hard capsules, dispersed within a soft gelatin capsule, or combined with appropriate excipients and tableted by compression.
  • Dosage forms can include one or more drugs. If the drugs are compatible, several different drugs can be incorporated into the same microparticle composition or coated microparticle composition. The drugs can be incorporated into separate microparticle compositions where a first drug is formulated into microparticle compositions or coated microparticle compositions described herein and one or more additional drugs are incorporated into microparticle compostions or coated microparticle compositions described herein, sustained release compositions known in the art or immediate release compositions known in the art. The compositions including the different drugs are formulated into a single solid dosage form suitable for oral administration, for example, they can be incorporated into a gelatin capsule, or combined with appropriate excipients and compressed into a tablet form.
  • An immediate release dose can be incorporated into the formulation in several ways. Immediate release microparticles can be made utilizing standard methodologies and formulated along with sustained release microparticle and/or coated microparticle compositions in a suitable oral dosage form. Alternatively, a coating containing drug which is available for immediate release can be placed on a tablet including sustained release microparticle and/or coated microparticle compositions plus appropriate excipients. Additionally, an immediate dose of drug can be granulated or blended with rapidly dissolving excipients and subsequently compressed (1) as one layer of bi-layer tablets in which the sustained release microparticle and/or coated microparticle compositions are compressed as the other layer, or (2) as the outer layer of compression-coated tablets in which the sustained release microparticle and/or coated microparticle compositions are compressed as the inner core, or (3) into tablets in which sustained release microparticle and/or coated microparticle compositions are embedded.
  • Optional excipients present in the oral dosage form including abuse deterrent microparticles or coated microparticles include, but are not limited to diluents, binders, lubricants, disintigrants, colorants, plasticizers and the like. Diluents, also termed “fillers,” are typically necessary to increase the bulk of a solid dosage form so that a practical size is provided for compression of tablets. Examples of diluents include cellulose, dry starch, microcrystalline cellulose, dicalcium phosphate, calcium sulfate, sodium chloride confectioner's sugar, compressible sugar, dextrates, dextrin, dextrose, sucrose, mannitol, powdered cellulose, sorbitol, and lactose. Binders are used to impart cohesive qualities powdered materials and can include materials such as starch, gelatin, sugars, natural and synthetic gums, polyethylene glycol, ethylcellulose, methylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, waxes and polyvinyl pyrrolidone. Lubricants are used to facilitate tablet manufacture; examples of lubricants include talc, magnesium stearate, calcium stearate, hydrogenated vegetable oils stearic acid, sodium stearyl fumarate, sodium benzoate, sodium acetate, leucine, sodium oleate, sodium lauryl sulfate, magnesium lauryl sulfate and polyethylene glycol. Disintegrants can be added to pharmaceutical formulations in order to facilitate “breakup” or disintegration after administration. Materials used for this purpose include starches, clays, celluloses, aligns, gums, and cross-linked polymers. A plasticizer may be included in coating materials to alter their mechanical properties. Examples of plasticizers include benzyl benzoate, chlorobutanol, dibutyl sebacate, diethyl phthalate, glycerin, mineral oil, polyethylene glycol, sorbitol, triacetin, triethyl citrate, glycerol, etc. In addition to the additives above, coloring and flavoring agents may also be incorporated into the composition.
  • II. Methods of Administration
  • It is assumed that upon oral ingestion of the intact composition, drug is released as the formulation is gradually broken down or dissolved within the GI tract by a combination of diffusion, surfactant action of bile acids, mechanical erosion, and, in some embodiments, enzymatic degradation. This is a result of the unique ability of the human digestive system to efficiently break down or solubilize a variety of materials. The process within the GI tract that results in the digestion of food and the absorption of nutrients is well known. Following mastication within the mouth, food passes into the stomach where it is mixed with digestive juices. This fluid contains the proteolytic enzyme pepsin which, following activation by the low pH within the stomach, begins the process of cleaving ingested proteins into smaller peptide fragments. Food then enters the small intestine in the form of macromolecular aggregates, where it is digested into molecules near or in a form capable of being absorbed. This digestion is accomplished through the action of various enzymes which are produced in the pancreas and flow into the upper portion of the large intestine, the duodenum. The enzymes synthesized in the pancreas include proteases, amylases and lipases; these enzymes are capable of breaking down proteins, starches and fats, respectively. The digestion of fats is further facilitated by the secretion of bile into the duodenum since bile salts, which contain both hydrophobic and hydrophilic portions, are capable of emulsifying lipids into minute droplets in order to increase the surface area available for digestion by lipases. The material which remains following passage through the small intestine enters the large intestine. Bacteria capable of breaking down carbohydrates not digested in the small intestine (such as cellulose) are present in large numbers this region of the digestive tract. Finally, in addition to microbial fermentation, the large intestine functions to absorb water and electrolytes and to form and store feces until they are excreted.
  • In some embodiments, an immediate release of drug is achieved within the stomach in order to provide rapid therapeutic onset.
  • The pharmaceutical drug composition is administered orally. The appropriate dosage formulations can be obtained by calculation of the pharmacokinetics of the formulation, then adjusting using routine techniques to yield the appropriate drug levels based on the approved dosage forms. Any suitable amount of drug containing microparticles or coated microparticles can be included in the final formulation. The selection of a suitable amount of drug containing microparticles depends on the dosage desired and is readily determined by those skilled in the art.
  • In addition to oral administration, some embodiments may also be administered by other routes, including, but not limited to, rectal and nasal administration. Some embodiments may also be suitable for formulation as oral liquids.
  • The present composition and method of making and using the composition will be further understood by reference to the following non-limiting examples.
  • EXAMPLE 1 Preparation of Lipophilic Oxycodone Derivative Oxycodone Free Base
  • The free base of oxycodone can be prepared from its hydrochloride salt by the following method: Oxycodone hydrochloride is dissolved in water and sodium carbonate was added in the amount required to neutralize hydrochloric acid. Methylene chloride is added in order to extract the formed oxycodone free base. The obtained organic layer is dried over sodium sulfate and methylene chloride is evaporated using rotary evaporator. The obtained oxycodone free base is purified by crystallization.
  • EXAMPLE 2 Preparation of Drug Containing Microparticles
  • TABLE 1
    Compositions
    Composition Composition Composition Composition
    of of of of
    Formulation Formulation Formulation Formulation
    Ingredient A B C D
    Oxycodone  5 g  5 g 10 g  5 g
    Base
    Myristic Acid 50 g 30 g
    Stearic Acid 34 g 34 g
    Yellow 10 g 10 g 10 g
    Beeswax
    Carnauba wax  5 g 10 g 20 g 10 g
  • Procedure:
  • 1. Fatty acid (myristic or stearic acid) was melted in an erlenmeyer flask in a silicone oil bath at 100° C. Note the composition was subjected to stirring and was kept under an argon blanket for this and all subsequent steps.
    2. Oxycodone base was introduced into the molten fatty acid and the melt was stirred until all oxycodone base dissolved and a clear liquid was formed.
    3. Yellow beeswax was added and melted under constant stirring.
    4. Carnauba wax was added and melted under constant stirring.
    5. The resulting homogeneous molten solution was poured onto aluminum foil and allowed to solidify at room temperature.
    6. The bulk wax obtained was combined with dry ice and subjected to size reduction in a mortar and pestle.
    7. The dry ice was allowed to dissipate and the particles were sieved to obtain various size ranges. Particles 20-40 mesh in size (400-841 micron) were subjected to testing.
  • EXAMPLE 3 Release of Drug from Crushed Microparticles
  • In vitro testing was conducted in order to assess the influence of crushing of the microparticles produced in Example 2 on the release in simulated stomach conditions. A currently marketed sustained release formulation of oxycodone, OxyContin®, was also subjected to crushing and dissolution for comparison purposes.
  • Microparticles (Formulations A, B, C or D, all 20-40 mesh in starting particle size) or tablets were crushed using a glass mortar & pestle. The resulting crushed material was placed in a dissolution vessel equipped with paddles (USP Apparatus II). 900 mL of 0.1N HCl pre-warmed to 37° C. was added to the vessels and stirring was conducted for 15 minutes. After 15 minutes the amount of oxycodone released was determined. See Table 2.
  • TABLE 2
    Oxycontin Formulations
    % Released in 15
    minutes in 0.1N HCl
    Sample (n = 3)
    Oxycontin ® 95.6 +/− 2.7
    (40 mg Tablet)
    Formulation A 31.6 +/− 2.6
    (microparticles containing 40 mg oxycodone HCl
    equivalent)
    Formulation B 19.7 +/− 1.4
    (microparticles containing 40 mg oxycodone HCl
    equivalent)
    Formulation C 14.8 +/− 1.1
    (microparticles containing 20 mg oxycodone HCl
    equivalent)
    Formulation D 18.2 +/− 1.6
    (microparticles containing 20 mg oxycodone HCl
    equivalent)
  • As illustrated in the table above, the microparticle compositions of Example 2 release only a fraction of the total drug load in simulated stomach conditions when crushed. In contrast, a currently marketed sustained release composition, OxyContin®, releases approximately 96% of the drug load when crushed and exposed to identical conditions.
  • EXAMPLE 4 Preparation of Coated Drug Containing Microparticles
  • The drug-containing particles from Example 2 are spray coated with cellulose acetate phalate.
  • EXAMPLE 5 Preparation of Capsules for Oral Administration
  • The drug containing microparticles from Example 2 and/or the coated microparticles from Example 3 are blended with a lubricant and incorporated into standard gelatin capsules.
  • Modifications and variations of the present invention will be obvious to those skilled in the art.

Claims (21)

1. An orally administrable sustained release pharmaceutical composition comprising a therapeutically effective amount of microparticles consisting of
(a) a lipophilic drug or lipophilic derivative of a drug other than a drug prone to abuse and
(b) one or more carrier materials selected from the group consisting of fats, fatty substances, waxes, wax-like substances and mixtures thereof
wherein the drug is dispersed within the one or more carrier materials, and the release of a portion of incorporated drug is retarded when the physical integrity of the composition is compromised and the compromised composition is exposed to 0.1N HCl.
2. An orally administrable sustained release pharmaceutical composition comprising a therapeutically effective amount of microparticles consisting of a lipophilic derivative of a drug other than a drug prone to abuse dispersed within one or more carrier materials which are either slowly soluble in water or insoluble in water, wherein the release of a portion of incorporated drug is retarded when the physical integrity of the composition is compromised and the compromised composition is exposed to 0.1N HCl.
3. The composition of claim 1 or 2, wherein the portion of the drug released immediately when the physical integrity of the composition is compromised is less than 80% of the total amount of drug incorporated into formulation.
4. The composition of claim 1 or 2, wherein the lipophilic derivative of a drug is a free base or a free acid of the drug.
5. The composition of claim 1 or 2, wherein the lipophilic derivative of a drug is a salt comprising the ionized drug and a counter-ion.
6. The composition of claim 1 or 2, wherein the lipophilic derivative of a drug is an ester or amide formed between the drug and a fatty acid.
7. The composition of claim 5 wherein the counter-ion is selected from the group consisting of stearic acid, palmitic acid, myristic acid, and mixtures thereof.
8. The composition of claim 5 wherein the counter-ion is selected from the group consisting of methacrylic acid-methyl methacrylate copolymers, acrylic acid polymers, crosslinked acrylic acid polymers and carboxymethylcellulose.
9. The composition of claim 2 wherein the microparticles consist of drug dispersed in a material selected from the group consisting of fats, fatty substances, waxes, wax-like substances and mixtures thereof.
10. The composition of claim 1 or 2 comprising one or more carrier materials selected from the group consisting of stearic acid, palmitic acid, and mixtures thereof.
11. The composition of claim 1 or 2 comprising one or more carrier materials selected from the group consisting of beeswax, carnauba wax, hydrogenated oil, and mixtures thereof.
12. The composition of claim 1 or 2 wherein the carrier materials are selected from the group consisting of myristic acid, palmitic acid, stearic acid, carnauba wax, beeswax and mixtures thereof.
13. The composition of claim 2 wherein the microparticles consist of a drug dispersed in a carrier material selected from the group consisting of naturally water insoluble proteins, naturally water insoluble polysaccharides, naturally water insoluble lipids and phospholipids, cross-linked water soluble proteins, cross-linked water soluble polysaccharides and combinations thereof.
14. The composition of claim 1 or 2 wherein the individual microparticles are coated with one or more independent layers.
15. The composition of claim 14 wherein the coated layer(s) comprise a material selected from the group consisting of naturally water insoluble proteins, naturally water insoluble polysaccharides, naturally water insoluble lipids and phospholipids, cross-linked proteins, cross-linked polysaccharides, mixtures of waxes and fatty substances, and combinations thereof.
16. The composition of claim 15 wherein the coated layer(s) comprise a material selected from the group of pH dependent coatings, water insoluble diffusion barrier coatings, water soluble coatings and combinations thereof.
17. The composition of claim 1 or 2 wherein the lipophilic derivative is dissolved in the carrier material in a molten state to result in a uniform dispersion within the carrier material.
18. The composition of claim 1 or 2 wherein the lipophilic derivative is dissolved in a co-solvent along with a carrier material to result in a uniform dispersion within the carrier material.
19. The composition of claim 1 or 2, wherein the individual microparticles are further formulated into a tablet or capsule for oral administration.
20. The composition of claim 19, wherein the individual microparticles contain one or more drugs.
21. The composition of claim 19, wherein the tablet or capsule further comprises one or more drugs formulated as an immediate release dose, a sustained release dose, a delayed release dose, or a combination thereof.
US12/112,937 2002-07-05 2008-04-30 Sustained release compositions of drugs Abandoned US20080260819A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
US12/112,937 US20080260819A1 (en) 2002-07-05 2008-04-30 Sustained release compositions of drugs
US12/473,073 US8557291B2 (en) 2002-07-05 2009-05-27 Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US12/965,572 US8840928B2 (en) 2002-07-05 2010-12-10 Tamper-resistant pharmaceutical compositions of opioids and other drugs
US14/054,513 US9248195B2 (en) 2002-07-05 2013-10-15 Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US14/320,086 US9682075B2 (en) 2002-07-05 2014-06-30 Tamper-resistant pharmaceutical compositions of opioids and other drugs
US14/321,125 US20150005332A1 (en) 2002-07-05 2014-07-01 Tamper-resistant pharmaceutical compositions of opioids and other drugs
US14/946,275 US9592200B2 (en) 2002-07-05 2015-11-19 Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US15/457,153 US20170182032A1 (en) 2002-07-05 2017-03-13 Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US15/606,112 US10004729B2 (en) 2002-07-05 2017-05-26 Tamper-resistant pharmaceutical compositions of opioids and other drugs
US15/727,134 US10525053B2 (en) 2002-07-05 2017-10-06 Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US16/017,099 US20190167662A1 (en) 2002-07-05 2018-06-25 Tamper-resistant pharmaceutical compositions of opioids and other drugs
US16/697,938 US20200093820A1 (en) 2002-07-05 2019-11-27 Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US16/932,647 US20200345723A1 (en) 2002-07-05 2020-07-17 Abuse-deterrent pharmaceutical compositions of opioids and other drugs

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US39387602P 2002-07-05 2002-07-05
US43652302P 2002-12-23 2002-12-23
US44322603P 2003-01-28 2003-01-28
US46351803P 2003-04-15 2003-04-15
US46351403P 2003-04-15 2003-04-15
US10/614,866 US7399488B2 (en) 2002-07-05 2003-07-07 Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US12/112,937 US20080260819A1 (en) 2002-07-05 2008-04-30 Sustained release compositions of drugs

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/614,866 Continuation-In-Part US7399488B2 (en) 2002-07-05 2003-07-07 Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US12/473,073 Continuation-In-Part US8557291B2 (en) 2002-07-05 2009-05-27 Abuse-deterrent pharmaceutical compositions of opioids and other drugs

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/614,866 Continuation-In-Part US7399488B2 (en) 2002-07-05 2003-07-07 Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US12/473,073 Continuation-In-Part US8557291B2 (en) 2002-07-05 2009-05-27 Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US12/965,572 Continuation-In-Part US8840928B2 (en) 2002-07-05 2010-12-10 Tamper-resistant pharmaceutical compositions of opioids and other drugs

Publications (1)

Publication Number Publication Date
US20080260819A1 true US20080260819A1 (en) 2008-10-23

Family

ID=30119451

Family Applications (6)

Application Number Title Priority Date Filing Date
US10/614,866 Active 2025-03-24 US7399488B2 (en) 2002-07-05 2003-07-07 Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US12/112,993 Abandoned US20080199530A1 (en) 2002-07-05 2008-04-30 Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US12/112,937 Abandoned US20080260819A1 (en) 2002-07-05 2008-04-30 Sustained release compositions of drugs
US13/551,455 Expired - Lifetime US9044398B2 (en) 2002-07-05 2012-07-17 Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US14/717,232 Abandoned US20150265596A1 (en) 2002-07-05 2015-05-20 Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US15/725,818 Abandoned US20180028528A1 (en) 2002-07-05 2017-10-05 Abuse-deterrent pharmaceutical compositions of opioids and other drugs

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US10/614,866 Active 2025-03-24 US7399488B2 (en) 2002-07-05 2003-07-07 Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US12/112,993 Abandoned US20080199530A1 (en) 2002-07-05 2008-04-30 Abuse-deterrent pharmaceutical compositions of opioids and other drugs

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13/551,455 Expired - Lifetime US9044398B2 (en) 2002-07-05 2012-07-17 Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US14/717,232 Abandoned US20150265596A1 (en) 2002-07-05 2015-05-20 Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US15/725,818 Abandoned US20180028528A1 (en) 2002-07-05 2017-10-05 Abuse-deterrent pharmaceutical compositions of opioids and other drugs

Country Status (6)

Country Link
US (6) US7399488B2 (en)
EP (1) EP1594467A4 (en)
JP (5) JP4694207B2 (en)
AU (1) AU2003247876B2 (en)
CA (1) CA2491572C (en)
WO (1) WO2004004693A1 (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050281748A1 (en) * 2004-06-12 2005-12-22 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US20080199530A1 (en) * 2002-07-05 2008-08-21 Collegium Pharmaceuticals Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US20090297617A1 (en) * 2002-07-05 2009-12-03 Collegium Pharmaceuticals Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US20100307542A1 (en) * 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Method of Reducing Surface Oil on Encapsulated Material
US20100310666A1 (en) * 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Delivery of Functional Compounds
US20100310726A1 (en) * 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Novel Preparation of an Enteric Release System
US20110076325A1 (en) * 2007-08-13 2011-03-31 Abuse Deterrent Pharmaceutical, Llc Abuse resistant drugs, method of use and method of making
US20110142943A1 (en) * 2002-07-05 2011-06-16 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opiods and other drugs
US20110159103A1 (en) * 2009-06-05 2011-06-30 Kraft Foods Global Brands Llc Novel Preparation of an Enteric Release System
US20110223247A1 (en) * 2008-11-07 2011-09-15 Samyang Corporation Pharmaceutical compositions for release control of methylphenidate
WO2012097144A1 (en) * 2011-01-12 2012-07-19 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
WO2013049749A3 (en) * 2011-09-29 2013-07-11 Plx Pharma Inc. pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US8859005B2 (en) 2012-12-03 2014-10-14 Intercontinental Great Brands Llc Enteric delivery of functional ingredients suitable for hot comestible applications
US8940729B1 (en) * 2007-05-22 2015-01-27 Pisgah Laboratories, Inc. Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US9999626B2 (en) 2014-06-18 2018-06-19 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of active agents
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US10130719B2 (en) 2016-06-03 2018-11-20 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US10420726B2 (en) 2013-03-15 2019-09-24 Inspirion Delivery Sciences, Llc Abuse deterrent compositions and methods of use
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
WO2021195319A1 (en) * 2020-03-26 2021-09-30 Plx Opco Inc. PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND- METHODS FOR MAKING AND USING SAME

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
KR100417489B1 (en) 1997-12-22 2004-02-05 유로-셀티크 소시에떼 아노뉨 Opioid agonist/antagonist combinations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
HU230828B1 (en) 1999-10-29 2018-08-28 Euro Celtique Sa Controlled release hydrocodone formulations
WO2002036099A1 (en) 2000-10-30 2002-05-10 Euro-Celtique S.A. Controlled release hydrocodone formulations
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20030065002A1 (en) 2001-05-11 2003-04-03 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
CA2708900C (en) 2002-04-05 2019-06-04 Purdue Pharma Pharmaceutical preparation containing oxycodone and naloxone
KR101061351B1 (en) 2002-04-09 2011-08-31 플라멜 테크놀로지스 Oral Suspension of Active Ingredient Microcapsules
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
DE102004020220A1 (en) * 2004-04-22 2005-11-10 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004032051A1 (en) * 2004-07-01 2006-01-19 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
DE10336400A1 (en) * 2003-08-06 2005-03-24 Grünenthal GmbH Anti-abuse dosage form
ATE365545T1 (en) * 2003-08-06 2007-07-15 Gruenenthal Gmbh DOSAGE FORM PROVEN AGAINST ABUSE
DE10361596A1 (en) 2003-12-24 2005-09-29 Grünenthal GmbH Process for producing an anti-abuse dosage form
DE102005005446A1 (en) * 2005-02-04 2006-08-10 Grünenthal GmbH Break-resistant dosage forms with sustained release
US20070048228A1 (en) * 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
TW201509943A (en) * 2004-03-30 2015-03-16 Euro Celtique Sa Oxycodone hydrochloride composition, pharmaceutical dosage form, sustained release oral dosage form and pharmaceutically acceptable package having less than 25 PPM 14-hydroxycodeinone
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1765303B2 (en) * 2004-07-01 2022-11-23 Grünenthal GmbH Oral tablet safeguarded against abuse
WO2006002886A1 (en) * 2004-07-01 2006-01-12 Grünenthal GmbH Oral dosage form safeguarded against abuse containing (1r, 2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
DE102004032049A1 (en) * 2004-07-01 2006-01-19 Grünenthal GmbH Anti-abuse, oral dosage form
US7226619B1 (en) 2004-09-07 2007-06-05 Pharmorx Inc. Material for controlling diversion of medications
ES2531735T3 (en) * 2004-10-15 2015-03-18 Supernus Pharmaceuticals, Inc. Pharmaceutical preparations with lower potential for abuse
FR2878161B1 (en) * 2004-11-23 2008-10-31 Flamel Technologies Sa ORAL MEDICINE FORM, SOLID AND DESIGNED TO AVOID MEASUREMENT
FR2878158B1 (en) * 2004-11-24 2009-01-16 Flamel Technologies Sa ORAL PHARMACEUTICAL FORM, SOLID MICROPARTICULAR DESIGNED TO PREVENT MEASUREMENT
EP2319499A1 (en) 2005-01-28 2011-05-11 Euro-Celtique S.A. Alcohol resistant dosage forms
DE102005005449A1 (en) * 2005-02-04 2006-08-10 Grünenthal GmbH Process for producing an anti-abuse dosage form
FR2881652B1 (en) * 2005-02-08 2007-05-25 Flamel Technologies Sa MICROPARTICULAR ORAL PHARMACEUTICAL FORM ANTI-MEASURING
FR2889810A1 (en) * 2005-05-24 2007-02-23 Flamel Technologies Sa ORAL MEDICINAL FORM, MICROPARTICULAR, ANTI-MEASUREMENT
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
WO2006133733A1 (en) * 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
RU2008104638A (en) * 2005-07-07 2009-08-20 Фарнэм Компаниз, Инк. (Us) PHARMACEUTICAL COMPOSITIONS OF WELL-SOLUBLE MEDICINAL PRODUCTS IN WATER, PROVIDING THEIR Slow-Motion Release
EP1951208A2 (en) * 2005-10-26 2008-08-06 Banner Pharmacaps Inc. Lipophilic vehicle-based dual controlled release matrix system as capsule fill
CA2627292C (en) * 2005-10-26 2012-04-17 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
WO2008134071A1 (en) * 2007-04-26 2008-11-06 Theraquest Biosciences, Inc. Multimodal abuse resistant extended release formulations
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
US8329744B2 (en) * 2005-11-02 2012-12-11 Relmada Therapeutics, Inc. Methods of preventing the serotonin syndrome and compositions for use thereof
US20100210732A1 (en) * 2005-11-02 2010-08-19 Najib Babul Methods of Preventing the Serotonin Syndrome and Compositions for Use Therefor
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
FR2892937B1 (en) * 2005-11-10 2013-04-05 Flamel Tech Sa MICROPARTICULAR ORAL PHARMACEUTICAL FORM ANTI-MEASURING
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
US20090317355A1 (en) * 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
US20100172989A1 (en) * 2006-01-21 2010-07-08 Abbott Laboratories Abuse resistant melt extruded formulation having reduced alcohol interaction
JP2009533443A (en) * 2006-04-10 2009-09-17 シャイア エルエルシー Mono- and disubstituted oxycodone compounds and compositions
US20100144645A1 (en) * 2006-04-14 2010-06-10 Shire Llc Compositions and methods for enhancing analgesic potency of covalently bound-compounds, attenuating its adverse side effects, and preventing their abuse
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
AU2007275034A1 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
US7976872B2 (en) * 2006-07-24 2011-07-12 L. Perrigo Company Method for distributing a pharmaceutically active compound in an excipient
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
US8187636B2 (en) * 2006-09-25 2012-05-29 Atlantic Pharmaceuticals, Inc. Dosage forms for tamper prone therapeutic agents
DE102007011485A1 (en) 2007-03-07 2008-09-11 Grünenthal GmbH Dosage form with more difficult abuse
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
RU2493830C2 (en) 2008-01-25 2013-09-27 Грюненталь Гмбх Drug form
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
AU2009243681B2 (en) * 2008-05-09 2013-12-19 Grunenthal Gmbh Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
MY150600A (en) * 2008-07-07 2014-01-30 Euro Celtique Sa Use of opioid antagonists for treating urinary retention
US10668012B2 (en) * 2008-09-04 2020-06-02 Farnam Companies, Inc. Chewable sustained release formulations
WO2010066034A1 (en) * 2008-12-12 2010-06-17 Paladin Labs Inc. Methadone formulation
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
PT2405915T (en) 2009-03-10 2019-01-29 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
PL2456427T3 (en) 2009-07-22 2015-07-31 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
EP2997965B1 (en) 2009-07-22 2019-01-02 Grünenthal GmbH Tamper-resistant dosage form for oxidation-sensitive opioids
CN108159019A (en) * 2009-12-02 2018-06-15 阿黛尔药物有限公司 Fexofenadine microcapsules and the composition containing fexofenadine microcapsules
US9125867B2 (en) * 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
PL2560624T3 (en) 2010-04-23 2019-01-31 Kempharm, Inc. Therapeutic formulation for reduced drug side effects
CA2798702A1 (en) 2010-05-11 2011-11-17 Cima Labs Inc. Alcoholresistant metoprolol-containing extended-release oral dosage forms
TWI516286B (en) 2010-09-02 2016-01-11 歌林達股份有限公司 Tamper resistant dosage form comprising an anionic polymer
MX2013002377A (en) 2010-09-02 2013-04-29 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt.
SG191288A1 (en) 2010-12-22 2013-07-31 Purdue Pharma Lp Encased tamper resistant controlled release dosage forms
ES2581323T3 (en) 2010-12-23 2016-09-05 Purdue Pharma Lp Solid oral dosage forms resistant to alterations
BR112014001091A2 (en) 2011-07-29 2017-02-14 Gruenenthal Gmbh tamper resistant tablet that provides immediate release of the drug
LT2736495T (en) 2011-07-29 2017-11-10 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
EP2768481A4 (en) * 2011-10-21 2015-07-08 Subhash Desai Compositions for reduction of side effects
BR112014019988A8 (en) 2012-02-28 2017-07-11 Gruenenthal Gmbh BREAK-RESISTANT DOSAGE FORM COMPRISING A PHARMACOLOGICALLY ACTIVE COMPOUND AND AN ANIONIC POLYMER
AR090695A1 (en) 2012-04-18 2014-12-03 Gruenenthal Gmbh PHARMACEUTICAL DOSAGE FORM RESISTANT TO ADULTERATION AND RESISTANT TO IMMEDIATE RELEASE OF DOSE
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10420729B2 (en) 2013-03-15 2019-09-24 R.P. Scherer Technologies, Llc Abuse resistant capsule
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
JP6466417B2 (en) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング A tamper-resistant dosage form with a bimodal release profile
CA2907950A1 (en) * 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
MX368846B (en) 2013-07-12 2019-10-18 Gruenenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer.
MY183489A (en) 2013-07-23 2021-02-22 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
CA2931553C (en) 2013-11-26 2022-01-18 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
US8846923B1 (en) 2013-12-18 2014-09-30 Cody Laboratories, Inc. Preparation of 14-hydroxycodeinone sulfate
US9062062B1 (en) 2013-12-18 2015-06-23 Cody Laboratories, Inc. Synthesis of oxycodone hydrochloride
US10227354B2 (en) 2013-12-18 2019-03-12 Cody Laboratories, Inc. Conversion of oxycodone base to oxycodone hydrochloride
CA2938699A1 (en) 2014-02-05 2015-08-13 Kashiv Pharma Llc Abuse-resistant drug formulations with built-in overdose protection
US10772841B2 (en) * 2014-04-07 2020-09-15 Patheon Softgels Inc. Opioid abuse-deterrent controlled release formulations
CA2947786A1 (en) 2014-05-12 2015-11-19 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
EP3285745A1 (en) 2015-04-24 2018-02-28 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (en) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Protection against oral overdose with abuse-inhibiting immediate release formulations
EP3210630A1 (en) * 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10624856B2 (en) 2018-01-31 2020-04-21 Dharma Laboratories LLC Non-extractable oral solid dosage forms
WO2020070547A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
KR20210074275A (en) 2018-10-05 2021-06-21 클렉시오 바이오사이언시스 리미티드 Dosage regimen of esketamine to treat major depressive disorder
WO2020070706A1 (en) 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
EP3863617A1 (en) 2018-10-11 2021-08-18 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
EP3965733A4 (en) 2019-05-07 2023-01-11 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
WO2021137147A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder
WO2021137148A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions

Citations (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2404319A (en) * 1941-06-28 1946-07-16 Wm S Merrell Co Butanolamine salts of theophylline
US3015128A (en) * 1960-08-18 1962-01-02 Southwest Res Inst Encapsulating apparatus
US3336200A (en) * 1963-05-28 1967-08-15 Warner Lambert Pharmaceutical Tablet structure
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
US3980766A (en) * 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US4070494A (en) * 1975-07-09 1978-01-24 Bayer Aktiengesellschaft Enteral pharmaceutical compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4569937A (en) * 1985-02-11 1986-02-11 E. I. Du Pont De Nemours And Company Analgesic mixture of oxycodone and ibuprofen
US4599326A (en) * 1984-01-06 1986-07-08 Orion-Yhtyma Oy Acetyl erythromycin stearate, and compositions containing it
US4675140A (en) * 1984-05-18 1987-06-23 Washington University Technology Associates Method for coating particles or liquid droplets
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4869904A (en) * 1986-12-26 1989-09-26 Nisshin Flour Milling Co., Ltd. Sustained release drug preparation
EP0375063A1 (en) * 1988-12-20 1990-06-27 Yamanouchi Europe B.V. Granulates for multiparticulate controlled-release oral compositions
US5190947A (en) * 1990-08-23 1993-03-02 Ciba-Geigy Corporation Codeine salt of a substituted carboxylic acid, its use and pharmaceutical compositions thereof
US5356467A (en) * 1992-08-13 1994-10-18 Euroceltique S.A. Controlled release coatings derived from aqueous dispersions of zein
US5460826A (en) * 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5508042A (en) * 1991-11-27 1996-04-16 Euro-Celtigue, S.A. Controlled release oxycodone compositions
US5756483A (en) * 1993-03-26 1998-05-26 Merkus; Franciscus W. H. M. Pharmaceutical compositions for intranasal administration of apomorphine
US5849240A (en) * 1993-11-23 1998-12-15 Euro-Celtique, S.A. Method of preparing sustained release pharmaceutical compositions
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5914129A (en) * 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
US5952005A (en) * 1993-03-30 1999-09-14 Pharmacia & Upjohn Aktiebolag Controlled release preparation for administering morphine
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5958452A (en) * 1994-11-04 1999-09-28 Euro-Celtique, S.A. Extruded orally administrable opioid formulations
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6068855A (en) * 1994-11-03 2000-05-30 Euro-Celtique S. A. Pharmaceutical composition containing a fusible carrier and method for producing the same
US6103261A (en) * 1993-07-01 2000-08-15 Purdue Pharma Lp Opioid formulations having extended controlled release
US6156764A (en) * 1996-02-28 2000-12-05 Lts Lohmann Therapie-Systeme Gmbh Morphine and diamorphine salts of anionic non-narcotic analgesics of the substituted carboxylic acid type
US6255502B1 (en) * 1996-07-11 2001-07-03 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
US20010006650A1 (en) * 1997-09-19 2001-07-05 Beth A. Burnside Solid solution beadlet
US6277384B1 (en) * 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US6290990B1 (en) * 1994-04-18 2001-09-18 Basf Aktiengesellschaft Slow-release matrix pellets and the production thereof
US6310072B1 (en) * 1995-10-19 2001-10-30 The University Of Queensland Production of analgesic synergy by co-administration of sub-analgesic doses of a MU opioid agonist and a kappa-2 opioid agonist
US6309668B1 (en) * 1994-02-01 2001-10-30 Aventis Pharma Limited Abuse resistant tablets
US6328979B1 (en) * 1997-12-26 2001-12-11 Yamanouchi Pharmaceuticals, Co. Ltd. Sustained release medicinal compositions
US20020032166A1 (en) * 1992-10-14 2002-03-14 University Technology Corporation Biocompatible cationic detergents and uses therefor
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6379707B2 (en) * 1999-03-24 2002-04-30 Fmc Corporation Method of making granular pharmaceutical vehicle
US20030059397A1 (en) * 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
US20030064099A1 (en) * 2001-08-06 2003-04-03 Benjamin Oshlack Pharmaceutical formulation containing bittering agent
US6696088B2 (en) * 2000-02-08 2004-02-24 Euro-Celtique, S.A. Tamper-resistant oral opioid agonist formulations
US20040052731A1 (en) * 2002-07-05 2004-03-18 Collegium Pharmaceuticals, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
US6723343B2 (en) * 1999-08-31 2004-04-20 Gruenenthal Gmbh Pharmaceutical tramadol salts
US20050013862A1 (en) * 2001-09-05 2005-01-20 Vectura Limited Functional powders for oral delivery
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
US20050281748A1 (en) * 2004-06-12 2005-12-22 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US7011846B2 (en) * 2001-12-21 2006-03-14 Shire Laboratories, Inc. Oral capsule formulation with increased physical stability
US20060104909A1 (en) * 2002-09-23 2006-05-18 Farid Vaghefi Abuse-resistant pharmaceutical compositions
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US7670612B2 (en) * 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20110142943A1 (en) * 2002-07-05 2011-06-16 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opiods and other drugs
US8557291B2 (en) * 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2426812A1 (en) 1974-06-04 1976-01-02 Klinge Co Chem Pharm Fab PROCESS FOR THE MANUFACTURING OF GRANULES
SI9200139A (en) 1992-07-08 1994-03-31 Lek Tovarna Farmacevtskih New inclusion complex of clavulanic acid with hydrophylyc and hydropholyc beta-cyclodextrin derivates for production of them
EP0647448A1 (en) 1993-10-07 1995-04-12 Euroceltique S.A. Orally administrable opioid formulations having extended duration of effect
JP2000512649A (en) 1996-06-27 2000-09-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Sustained release sufentanil composition
EP0934341A1 (en) 1996-10-28 1999-08-11 Farmac Nederland B.V. Inclusion complexes of beta-2-andrenergics for oral mucosal delivery
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
JP2003522127A (en) 1999-07-29 2003-07-22 ロクセニ ラボラトリーズ インコーポレイテッド Opioid sustained release formulation
WO2001072338A1 (en) 2000-03-28 2001-10-04 Farmarc Nederland Bv Alprazolam inclusion complexes and pharmaceutical compositions thereof
BR0210855A (en) 2001-07-06 2006-10-24 Penwest Pharmaceuticals Compan Method of Manufacturing Extended Release Formulations
US10004729B2 (en) * 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
CN1777411B (en) 2003-02-24 2013-01-02 药品生产公司 Transmucosal drug delivery system
WO2008027283A2 (en) * 2006-08-25 2008-03-06 Dow Global Technologies Inc. Production of meta-block copolymers by polymer segment interchange
US9737530B1 (en) * 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations

Patent Citations (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2404319A (en) * 1941-06-28 1946-07-16 Wm S Merrell Co Butanolamine salts of theophylline
US3015128A (en) * 1960-08-18 1962-01-02 Southwest Res Inst Encapsulating apparatus
US3336200A (en) * 1963-05-28 1967-08-15 Warner Lambert Pharmaceutical Tablet structure
US3773955A (en) * 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US3980766A (en) * 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3966940A (en) * 1973-11-09 1976-06-29 Bristol-Myers Company Analgetic compositions
US4070494A (en) * 1975-07-09 1978-01-24 Bayer Aktiengesellschaft Enteral pharmaceutical compositions
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4599326A (en) * 1984-01-06 1986-07-08 Orion-Yhtyma Oy Acetyl erythromycin stearate, and compositions containing it
US4675140A (en) * 1984-05-18 1987-06-23 Washington University Technology Associates Method for coating particles or liquid droplets
US4569937A (en) * 1985-02-11 1986-02-11 E. I. Du Pont De Nemours And Company Analgesic mixture of oxycodone and ibuprofen
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US4869904A (en) * 1986-12-26 1989-09-26 Nisshin Flour Milling Co., Ltd. Sustained release drug preparation
EP0375063A1 (en) * 1988-12-20 1990-06-27 Yamanouchi Europe B.V. Granulates for multiparticulate controlled-release oral compositions
US5190947A (en) * 1990-08-23 1993-03-02 Ciba-Geigy Corporation Codeine salt of a substituted carboxylic acid, its use and pharmaceutical compositions thereof
US5508042A (en) * 1991-11-27 1996-04-16 Euro-Celtigue, S.A. Controlled release oxycodone compositions
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US20020081333A1 (en) * 1991-12-24 2002-06-27 Benjamin Oshlack Orally administrable opioid formulations having extended duration of effect
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US6294195B1 (en) * 1991-12-24 2001-09-25 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5356467A (en) * 1992-08-13 1994-10-18 Euroceltique S.A. Controlled release coatings derived from aqueous dispersions of zein
US20020032166A1 (en) * 1992-10-14 2002-03-14 University Technology Corporation Biocompatible cationic detergents and uses therefor
US5756483A (en) * 1993-03-26 1998-05-26 Merkus; Franciscus W. H. M. Pharmaceutical compositions for intranasal administration of apomorphine
US5952005A (en) * 1993-03-30 1999-09-14 Pharmacia & Upjohn Aktiebolag Controlled release preparation for administering morphine
US6103261A (en) * 1993-07-01 2000-08-15 Purdue Pharma Lp Opioid formulations having extended controlled release
US5965163A (en) * 1993-11-23 1999-10-12 Euro-Celtique, S.A. Substained release compositions and a method of preparing pharmaceutical compositions
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5849240A (en) * 1993-11-23 1998-12-15 Euro-Celtique, S.A. Method of preparing sustained release pharmaceutical compositions
US6162467A (en) * 1993-11-23 2000-12-19 Euro-Celtique, S.A. Sustained release compositions and a method of preparing pharmaceutical compositions
US6309668B1 (en) * 1994-02-01 2001-10-30 Aventis Pharma Limited Abuse resistant tablets
US6290990B1 (en) * 1994-04-18 2001-09-18 Basf Aktiengesellschaft Slow-release matrix pellets and the production thereof
US5460826A (en) * 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US6068855A (en) * 1994-11-03 2000-05-30 Euro-Celtique S. A. Pharmaceutical composition containing a fusible carrier and method for producing the same
US6335033B2 (en) * 1994-11-04 2002-01-01 Euro-Celtique, S.A. Melt-extrusion multiparticulates
US5958452A (en) * 1994-11-04 1999-09-28 Euro-Celtique, S.A. Extruded orally administrable opioid formulations
US6261599B1 (en) * 1994-11-04 2001-07-17 Euro-Celtique, S.A. Melt-extruded orally administrable opioid formulations
US6706281B2 (en) * 1994-11-04 2004-03-16 Euro-Celtique, S.A. Melt-extrusion multiparticulates
US6743442B2 (en) * 1994-11-04 2004-06-01 Euro-Celtique, S.A. Melt-extruded orally administrable opioid formulations
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20010036476A1 (en) * 1994-11-04 2001-11-01 Euro-Celtique S.A. Melt-extruded orally administrable opioid formulations
US6310072B1 (en) * 1995-10-19 2001-10-30 The University Of Queensland Production of analgesic synergy by co-administration of sub-analgesic doses of a MU opioid agonist and a kappa-2 opioid agonist
US6156764A (en) * 1996-02-28 2000-12-05 Lts Lohmann Therapie-Systeme Gmbh Morphine and diamorphine salts of anionic non-narcotic analgesics of the substituted carboxylic acid type
US6255502B1 (en) * 1996-07-11 2001-07-03 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
US5914129A (en) * 1996-07-23 1999-06-22 Mauskop; Alexander Analgesic composition for treatment of migraine headaches
US20010006650A1 (en) * 1997-09-19 2001-07-05 Beth A. Burnside Solid solution beadlet
US6692767B2 (en) * 1997-09-19 2004-02-17 Shire Laboratories Inc. Solid solution beadlet
US6375957B1 (en) * 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6277384B1 (en) * 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US6475494B2 (en) * 1997-12-22 2002-11-05 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US6328979B1 (en) * 1997-12-26 2001-12-11 Yamanouchi Pharmaceuticals, Co. Ltd. Sustained release medicinal compositions
US6919372B1 (en) * 1997-12-26 2005-07-19 Yamanouchi Pharmaceutical Co., Ltd. Sustained release pharmaceutical compositions
US6048736A (en) * 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6379707B2 (en) * 1999-03-24 2002-04-30 Fmc Corporation Method of making granular pharmaceutical vehicle
US6723343B2 (en) * 1999-08-31 2004-04-20 Gruenenthal Gmbh Pharmaceutical tramadol salts
US6696088B2 (en) * 2000-02-08 2004-02-24 Euro-Celtique, S.A. Tamper-resistant oral opioid agonist formulations
US20030064099A1 (en) * 2001-08-06 2003-04-03 Benjamin Oshlack Pharmaceutical formulation containing bittering agent
US20050013862A1 (en) * 2001-09-05 2005-01-20 Vectura Limited Functional powders for oral delivery
US20030059397A1 (en) * 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
US7011846B2 (en) * 2001-12-21 2006-03-14 Shire Laboratories, Inc. Oral capsule formulation with increased physical stability
US7670612B2 (en) * 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20130045960A1 (en) * 2002-07-05 2013-02-21 Collegium Pharmaceuticals, Inc. Abuse-Deterrent Pharmaceutical Compositions of Opiods and Other Drugs
US20110142943A1 (en) * 2002-07-05 2011-06-16 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opiods and other drugs
US20040052731A1 (en) * 2002-07-05 2004-03-18 Collegium Pharmaceuticals, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US8557291B2 (en) * 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US7399488B2 (en) * 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20080199530A1 (en) * 2002-07-05 2008-08-21 Collegium Pharmaceuticals Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US20060104909A1 (en) * 2002-09-23 2006-05-18 Farid Vaghefi Abuse-resistant pharmaceutical compositions
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
US20050181050A1 (en) * 2004-01-28 2005-08-18 Collegium Pharmaceutical, Inc. Dosage forms using drug-loaded ion exchange resins
US7771707B2 (en) * 2004-06-12 2010-08-10 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US20100260834A1 (en) * 2004-06-12 2010-10-14 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US20050281748A1 (en) * 2004-06-12 2005-12-22 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US8449909B2 (en) * 2004-06-12 2013-05-28 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US20130310413A1 (en) * 2004-06-12 2013-11-21 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US7261529B2 (en) * 2005-09-07 2007-08-28 Southwest Research Institute Apparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"castor oil, hydrogenated", European Pharmacopoeia V.5 "castor oil, hydrogenated" (p. 1197-1198) (2005) *
Buist et al., Structural Chemistry, Acta Crystallographica, Section C, C70: 220-224 (2014) *
Bush et al. (Annals of Allergy, 41: 13-17 (1978) (Abstract only) *
Chemical Abstract Society (CAS), Properties for HPMC (CAS reg. no. 9004-65-3) accessed 6/29/2013 *
Choi et al. (International Journal of Pharmaceutics, 203: 193-202 (2000) *
Lan et al. (Journal of Applied Polymer Science, 92: 2163-2168 (2004) *
Ozturk et al., Journal of Controlled Release, 14: 203-213 (1990) *
Raffin et al. (International Journal of Pharmaceutics, 324: 10-18 (2006) *
Redden et al. (International Journal of Pharmaceutics, 165: 87-96 (1998) *
Yow et al., The American Journal of Medicine, p. 613 (1954) *

Cited By (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9248195B2 (en) 2002-07-05 2016-02-02 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US10525053B2 (en) 2002-07-05 2020-01-07 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US9682075B2 (en) 2002-07-05 2017-06-20 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8840928B2 (en) 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US9044398B2 (en) 2002-07-05 2015-06-02 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US20110142943A1 (en) * 2002-07-05 2011-06-16 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opiods and other drugs
US20090297617A1 (en) * 2002-07-05 2009-12-03 Collegium Pharmaceuticals Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US20080199530A1 (en) * 2002-07-05 2008-08-21 Collegium Pharmaceuticals Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US9592200B2 (en) 2002-07-05 2017-03-14 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US10525052B2 (en) 2004-06-12 2020-01-07 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US8449909B2 (en) 2004-06-12 2013-05-28 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US9763883B2 (en) 2004-06-12 2017-09-19 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US20100260834A1 (en) * 2004-06-12 2010-10-14 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US8758813B2 (en) 2004-06-12 2014-06-24 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US20050281748A1 (en) * 2004-06-12 2005-12-22 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US7771707B2 (en) 2004-06-12 2010-08-10 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US8940729B1 (en) * 2007-05-22 2015-01-27 Pisgah Laboratories, Inc. Abuse deterrent and anti-dose dumping pharmaceutical salts useful for the treatment of attention deficit/hyperactivity disorder
US20110150991A1 (en) * 2007-08-13 2011-06-23 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US20110150969A1 (en) * 2007-08-13 2011-06-23 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US20110076325A1 (en) * 2007-08-13 2011-03-31 Abuse Deterrent Pharmaceutical, Llc Abuse resistant drugs, method of use and method of making
US7955619B2 (en) 2007-08-13 2011-06-07 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US10736852B2 (en) 2007-08-13 2020-08-11 OHEMO Life Sciences, Inc. Abuse resistant oral opioid formulations
US20110159090A1 (en) * 2007-08-13 2011-06-30 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US20110159089A1 (en) * 2007-08-13 2011-06-30 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US20110150990A1 (en) * 2007-08-13 2011-06-23 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US10688055B2 (en) 2007-08-13 2020-06-23 Inspirion Delivery Sciences, Llc Abuse resistant forms of extended release morphine, method of use and method of making
US10736851B2 (en) 2007-08-13 2020-08-11 Ohemo Life Sciences Inc. Abuse resistant forms of extended release morphine with oxycodone, method of use and method of making
US10736850B2 (en) 2007-08-13 2020-08-11 Ohemo Life Sciences Inc. Abuse resistant oral opioid formulations
US10729656B2 (en) 2007-08-13 2020-08-04 Ohemo Life Sciences Inc. Abuse resistant forms of immediate release oxycodone, method of use and method of making
US20110150970A1 (en) * 2007-08-13 2011-06-23 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US20110150971A1 (en) * 2007-08-13 2011-06-23 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US10729657B2 (en) 2007-08-13 2020-08-04 Ohemo Life Sciences Inc. Abuse resistant forms of extended release morphine, method of use and method of making
US10688052B2 (en) 2007-08-13 2020-06-23 Inspirion Delivery Sciences Llc Abuse resistant forms of extended release oxymorphone, method of use and method of making
US10702480B2 (en) 2007-08-13 2020-07-07 OHEMO Life Sciences, Inc. Abuse resistant forms of extended release morphine, method of use and method of making
US11045422B2 (en) 2007-08-13 2021-06-29 Oheno Life Sciences, Inc. Abuse resistant drugs, method of use and method of making
US10695298B2 (en) 2007-08-13 2020-06-30 Inspirion Delivery Sciences, Llc Abuse resistant forms of extended release hydromorphone, method of use and method of making
US10688051B2 (en) 2007-08-13 2020-06-23 Inspirion Delivery Sciences Llc Abuse resistant forms of extended release oxycodone, method of use, and method of making
US10688054B2 (en) 2007-08-13 2020-06-23 Inspirion Delivery Sciences Llc Abuse resistant forms of extended release morphine, method of use and method of making
US10688053B2 (en) 2007-08-13 2020-06-23 Inspirion Delivery Sciences, Llc Abuse resistant forms of extended release hydrocodone, method of use and method of making
US8465768B2 (en) * 2008-11-07 2013-06-18 Samyang Biopharmaceuticals Corporation Pharmaceutical compositions for release control of methylphenidate
US20110223247A1 (en) * 2008-11-07 2011-09-15 Samyang Corporation Pharmaceutical compositions for release control of methylphenidate
US9968564B2 (en) 2009-06-05 2018-05-15 Intercontinental Great Brands Llc Delivery of functional compounds
US10716765B2 (en) 2009-06-05 2020-07-21 Intercontinental Great Brands Llc Delivery of functional compounds
US8859003B2 (en) 2009-06-05 2014-10-14 Intercontinental Great Brands Llc Preparation of an enteric release system
US8765030B2 (en) 2009-06-05 2014-07-01 Intercontinental Great Brands Llc Preparation of an enteric release system
US20110159103A1 (en) * 2009-06-05 2011-06-30 Kraft Foods Global Brands Llc Novel Preparation of an Enteric Release System
US20100310726A1 (en) * 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Novel Preparation of an Enteric Release System
US20100310666A1 (en) * 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Delivery of Functional Compounds
US20100307542A1 (en) * 2009-06-05 2010-12-09 Kraft Foods Global Brands Llc Method of Reducing Surface Oil on Encapsulated Material
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
JP2014512333A (en) * 2011-01-12 2014-05-22 テティス・ファーマシューティカルズ・エルエルシー Lipid-lowering antidiabetic drugs
US9216951B2 (en) 2011-01-12 2015-12-22 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
WO2012097144A1 (en) * 2011-01-12 2012-07-19 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
US8901107B2 (en) 2011-01-12 2014-12-02 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
US9012507B2 (en) 2011-01-12 2015-04-21 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
KR20200118219A (en) * 2011-09-29 2020-10-14 피엘엑스 옵코 인코포레이티드 Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
KR102162901B1 (en) 2011-09-29 2020-10-08 피엘엑스 옵코 인코포레이티드 Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
KR102188840B1 (en) 2011-09-29 2020-12-10 피엘엑스 옵코 인코포레이티드 Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
KR102180667B1 (en) 2011-09-29 2020-11-20 피엘엑스 옵코 인코포레이티드 Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
US10179104B2 (en) 2011-09-29 2019-01-15 Plx Opco Inc. PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
US10786444B2 (en) 2011-09-29 2020-09-29 Plx Opco Inc. PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
WO2013049749A3 (en) * 2011-09-29 2013-07-11 Plx Pharma Inc. pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME
CN103957888A (en) * 2011-09-29 2014-07-30 PLx制药公司 Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
US9730884B2 (en) 2011-09-29 2017-08-15 Plx Opco Inc. pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
KR20200008032A (en) * 2011-09-29 2020-01-22 피엘엑스 옵코 인코포레이티드 Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
US10646431B2 (en) 2011-09-29 2020-05-12 Plx Opco Inc. PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
KR20140105436A (en) * 2011-09-29 2014-09-01 피엘엑스 파마 인코포레이티드 Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
US9216150B2 (en) 2011-09-29 2015-12-22 Plx Pharma Inc. pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
US9226892B2 (en) 2011-09-29 2016-01-05 Plx Pharma Inc. pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US8933124B2 (en) 2012-07-10 2015-01-13 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US8859005B2 (en) 2012-12-03 2014-10-14 Intercontinental Great Brands Llc Enteric delivery of functional ingredients suitable for hot comestible applications
US10420726B2 (en) 2013-03-15 2019-09-24 Inspirion Delivery Sciences, Llc Abuse deterrent compositions and methods of use
US11571390B2 (en) 2013-03-15 2023-02-07 Othemo Life Sciences, Inc. Abuse deterrent compositions and methods of use
US9505709B2 (en) 2014-05-05 2016-11-29 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US9999626B2 (en) 2014-06-18 2018-06-19 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of active agents
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US10478429B2 (en) 2015-10-07 2019-11-19 Patheon Softgels, Inc. Abuse deterrent dosage forms
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US11925688B2 (en) 2016-06-03 2024-03-12 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
US11191840B2 (en) 2016-06-03 2021-12-07 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
US11135298B2 (en) 2016-06-03 2021-10-05 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
US10130719B2 (en) 2016-06-03 2018-11-20 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10188644B2 (en) 2016-06-23 2019-01-29 Collegium Pharmaceutical, Inc Process of making stable abuse-deterrent oral formulations
US9968598B2 (en) 2016-06-23 2018-05-15 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10646485B2 (en) 2016-06-23 2020-05-12 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2021195319A1 (en) * 2020-03-26 2021-09-30 Plx Opco Inc. PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND- METHODS FOR MAKING AND USING SAME
US11648257B2 (en) 2020-03-26 2023-05-16 Plx Opco Inc. Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same
US11771708B2 (en) 2020-03-26 2023-10-03 Greenwood Brands, Llc Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same

Also Published As

Publication number Publication date
US7399488B2 (en) 2008-07-15
US20150265596A1 (en) 2015-09-24
JP2017101075A (en) 2017-06-08
JP2013216707A (en) 2013-10-24
JP4694207B2 (en) 2011-06-08
CA2491572A1 (en) 2004-01-15
JP2015166402A (en) 2015-09-24
EP1594467A4 (en) 2008-10-22
US20180028528A1 (en) 2018-02-01
CA2491572C (en) 2010-03-23
EP1594467A1 (en) 2005-11-16
US9044398B2 (en) 2015-06-02
AU2003247876A1 (en) 2004-01-23
US20040052731A1 (en) 2004-03-18
AU2003247876B2 (en) 2006-10-05
JP2009298822A (en) 2009-12-24
WO2004004693A1 (en) 2004-01-15
JP2006500426A (en) 2006-01-05
US20080199530A1 (en) 2008-08-21
US20130045960A1 (en) 2013-02-21

Similar Documents

Publication Publication Date Title
US20080260819A1 (en) Sustained release compositions of drugs
JP4053604B2 (en) Time-specific controlled release dosage formulation and method for producing the same
ES2226886T3 (en) FORM OF ADMINISTRATION OF DELAYED ACTION CONTAINING SQUARINATE OF TRAMADOL.
KR100280099B1 (en) Release Initiation Control and Release Rate Controlled Formulations
EP0239361B1 (en) Sustained-release pharmaceutical preparation
US4794001A (en) Formulations providing three distinct releases
KR101216270B1 (en) Controlled release hydrocodone formulations
US6632451B2 (en) Delayed total release two pulse gastrointestinal drug delivery system
JP2661646B2 (en) Sustained-release oral pharmaceutical composition, base for preparation thereof, and method for producing said composition
US4904476A (en) Formulations providing three distinct releases
US8709996B2 (en) Pharmaceutical treatment process using chitosan or derivative thereof
CA3053254C (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
EP0202051A2 (en) Therapeutic compositions for oral administration
EP0793959A1 (en) Controlled-release composition
JP2007509155A (en) Drugs containing quetiapine
WO2000006128A1 (en) Preparation capable of releasing drug at target site in intestine
JPH0759499B2 (en) Diffusion coated composite unit dose
JP2002527468A (en) Pulsating dose oral drug delivery system
EP1166777A1 (en) Taste masked pharmaceutical particles
KR20030013460A (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
KR20010073168A (en) New sustained release oral formulations
CN108697700A (en) Deuterated domperidone composition and the method for treating illness
WO2007106957A1 (en) Multiple units controlled-release floating dosage forms
JP2011500553A (en) Controlled release bioadhesive formulation targeting 5-colon of 5-aminosalicylic acid or its salts or metabolites
JP3134187B2 (en) Controlled release composition

Legal Events

Date Code Title Description
AS Assignment

Owner name: COLLEGIUM PHARMACEUTICAL, INC., RHODE ISLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FLEMING, ALISON B.;RARIY, ROMAN V.;HIRSH, JANE;AND OTHERS;REEL/FRAME:021203/0327;SIGNING DATES FROM 20080515 TO 20080616

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION